<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960490</url>
  </required_header>
  <id_info>
    <org_study_id>E6011-J081-202</org_study_id>
    <nct_id>NCT02960490</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics</brief_title>
  <official_title>A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group&#xD;
      comparison study in rheumatoid arthritis participants inadequately responding to biologics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 26, 2016</start_date>
  <completion_date type="Actual">November 25, 2019</completion_date>
  <primary_completion_date type="Actual">May 16, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Core Treatment Phase: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 12 Based on Non-responder Imputation (NRI)</measure>
    <time_frame>Week 12</time_frame>
    <description>The ACR20 response was defined as if the following 3 criteria (ACR components) were met: Greater than or equal to (&gt;=) 20 percent (%) reduction from baseline in the tender joint count (TJC) in 68 joints (TJC68); &gt;=20% reduction from baseline in the swollen joint count (SJC) in 66 joints (SJC66); &gt;=20% reduction from baseline in at least 3 of the following 5 assessments: Physician's Global Assessment of Disease Activity (visual analog scale [VAS]), Participant's Global Assessment of Disease Activity (VAS), Participant's Assessment of Pain (VAS), Health Assessment Questionnaire disability index (HAQ-DI), and C-reactive protein (CRP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an ACR20 Response at Weeks 2, 4, 8, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72 Based on NRI</measure>
    <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 16, 20, 24; Extension Phase: Weeks 2, 4, 8, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>The ACR20 response was defined as if the following 3 criteria (ACR components) were met: &gt;=20% reduction from baseline in the TJC in 68 joints (TJC68); &gt;=20% reduction from baseline in the SJC in 66 joints (SJC66); &gt;=20% reduction from baseline in at least 3 of the following 5 assessments: Physician's Global Assessment of Disease Activity (VAS), Participant's Global Assessment of Disease Activity (VAS), Participant's Assessment of Pain (VAS), HAQ-DI, and CRP. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an ACR50 Response at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72 Based on NRI</measure>
    <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>The ACR50 response was defined as if the following 3 criteria (ACR components) were met: &gt;=50% reduction from baseline in the TJC in 68 joints (TJC68); &gt;=50% reduction from baseline in the SJC in 66 joints (SJC66); &gt;=50% reduction from baseline in at least 3 of the following 5 assessments: Physician's Global Assessment of Disease Activity (VAS), Participant's Global Assessment of Disease Activity (VAS), Participant's Assessment of Pain (VAS), HAQ-DI, and CRP. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an ACR70 Response at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72 Based on NRI</measure>
    <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>The ACR70 response was defined as if the following 3 criteria (ACR components) were met: &gt;=70% reduction from baseline in the TJC in 68 joints (TJC68); &gt;=70% reduction from baseline in the SJC in 66 joints (SJC66); &gt;=70% reduction from baseline in at least 3 of the following 5 assessments: Physician's Global Assessment of Disease Activity (VAS), Participant's Global Assessment of Disease Activity (VAS), Participant's Assessment of Pain (VAS), HAQ-DI, and CRP. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tender Joint Counts (TJC) at Each Visit Based on Last Observation Carried Forward (LOCF)</measure>
    <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>A total of 28 joints were examined for tenderness by applying pressure to the joint line or by moving joints through their respective ranges of motion. Joints were examined for tenderness by applying pressure to the joint line or by moving joints through their respective ranges of motion. Tender joints were marked with tick or cross in corresponding frames of the Assessment Sheet for Tender Joint Counts. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Swollen Joint Counts (SJC) at Each Visit Based on LOCF</measure>
    <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>A total of 28 joints were examined for swollen joints. Swollen joints were marked with open circles in corresponding frames of the Assessment Sheet for Swollen Joint Counts. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant's Assessment of Pain Based on VAS Score at Each Visit Based on LOCF</measure>
    <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>Intensity and severity of pain associated with rheumatoid arthritis (RA) were indicated by the participant on a score sheet, Pain/disease activity assessments reported by the participant, by placing a mark on a 100 millimeter (mm) horizontal VAS. Pain assessments reported by the participant, by placing a mark on a 100 mm horizontal VAS. The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity). Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant's Global Assessment of Disease Activity Based on VAS Score at Each Visit Based on LOCF</measure>
    <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>Participants were evaluated on their disease activity of RA, and entered the result on the score sheet, disease activity assessments reported by the participant, by placing a mark on a 100 mm horizontal VAS. The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity). Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on VAS Score at Each Visit Based on LOCF</measure>
    <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>The Physician's Global Assessment of Disease Activity was recorded using the 100 mm horizontal VAS. Physician rated participant's RA disease activity on a scale ranged from 0-100 mm, where 0 indicated no disease activity (no arthritis) and 100 represented maximum disease activity (maximum arthritis). Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Each Visit Based on LOCF</measure>
    <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>Degree of disability was self-evaluated by participant using HAQ-DI.Assessment was made based on activities capable without any aids/devices.20-question instrument assessed degree of difficulty person had in accomplishing tasks in 8 functional areas(dressing,arising,eating,walking,hygiene,reaching,gripping,and activities of daily living).Responses in each functional area were scored from 0(indicated no difficulty)to 3(indicated inability to perform task in that area).Overall score computed as: sum of domain scores and divided by number of domains answered.Total possible score range:0-3 where 0=least difficulty and 3=extreme difficulty.Data for Core Treatment Phase from Week 0-10 is reported according to participant re-randomization in 4 arms at Week 12.Data reported for Extension Phase from Baseline to Week 24,is same data for Core Treatment Phase,but excluding participants who received at least 1 dose of drug and had at least 1 postdose primary efficacy measurement after Week 24-72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-reactive Protein (CRP) Values at Each Visit Based on LOCF</measure>
    <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>CRP of each participants was measured as a part of blood biochemical tests. A normal CRP value is less than (&lt;) 10 milligram per deciliter (mg/dL). A test result showing a CRP level greater than 10 mg/dL is a sign of chronic disease. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Erythrocyte Sedimentation Rate (ESR) Values at Each Visit Based on LOCF</measure>
    <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>ESR were a type of blood test. An ESR was used to monitor the arthritis condition. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score 28 (DAS28)-ESR Values at Each Visit Based on LOCF</measure>
    <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>The DAS28 index was a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, participant global assessment of disease activity score, and ESR value. Total score ranged between 0-10. A DAS28-ESR score of 5.1 or above=high disease activity, a value greater than (&gt;) 3.2 and less than or equal to (&lt;=) 5.1=moderate disease activity and value &lt;=3.2=low disease activity, value &lt;2.6=disease remission. A positive change in score indicates worsening, and a negative change indicates improvement. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28-CRP Values at Each Visit Based on LOCF</measure>
    <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>The DAS28 index was a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, participant global assessment of disease activity score, and CRP value. Total score ranged between 0-10. A DAS28-CRP score of 4.1 or above=high disease activity, a value &gt;2.7 and &lt;=4.1=moderate disease activity and a value &lt;=2.7=low disease activity, value &lt;2.3=disease remission. A positive change in score indicates worsening, and a negative change indicates improvement. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Simple Disease Activity Index (SDAI) Values at Each Visit Based on LOCF</measure>
    <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>The SDAI was calculated from tender joint counts of 28 (score range as 0-28), swollen joint counts of 28 (score range as 0-28), participant's global assessment of disease activity (score range as 0-10), physician global assessment of disease activity score (score range as 0-10), and CRP value (score range as 0-10). Total score ranged between 0-86. SDAI score of 26 or above=high disease activity, a value &gt;11 and &lt;=26=moderate disease activity and value &lt;=11=low disease activity, value &lt;=3.3=disease remission. Higher scores indicated higher disease activity. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Disease Activity Index (CDAI) Values at Each Visit Based on LOCF</measure>
    <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>The CDAI was calculated from tender joint counts of 28 (score range as 0-28), swollen joint counts of 28 (score range as 0-28), participant's global assessment of disease activity (score range as 0-10) and physician global assessment of disease activity (score range as 0-10). Total score ranged between 0-76. CDAI score of 22 or above=high disease activity, a value &gt;10 and &lt;=22=moderate disease activity, a value &lt;=10=low disease activity, and a value &lt;=2.8=disease remission. Higher scores indicated higher disease activity. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a European League Against Rheumatism (EULAR) Good, Moderate or No Response Using DAS28-ESR at Each Visit Based on NRI</measure>
    <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>The Disease Activity Score Based on 28-joints Count-ESR based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 &lt;=3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to &lt;=5.1 or change from baseline &gt;0.6 to &lt;=1.2 with DAS28 &lt;=5.1; non-responders: change from baseline &lt;=0.6 or change from baseline &gt;0.6 and &lt;=1.2 with DAS28 &gt;5.1. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a EULAR Good, Moderate or No Response Using DAS28-CRP at Each Visit Based on NRI</measure>
    <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>The Disease Activity Score Based on 28-joints Count-CRP based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 &lt;=3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to &lt;=5.1 or change from baseline &gt;0.6 to &lt;=1.2 with DAS28 &lt;=5.1; non-responders: change from baseline &lt;=0.6 or change from baseline &gt;0.6 and &lt;=1.2 with DAS28 &gt;5.1. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved SDAI Remission at Each Visit Based on NRI</measure>
    <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>The SDAI was calculated from tender joint counts of 28 (score range as 0-28), swollen joint counts of 28 (score range as 0-28), participant's global assessment of disease activity (score range as 0-10), physician global assessment of disease activity score (score range as 0-10), and CRP value (score range as 0-10). Total score ranged between 0-86. SDAI score of 86 or above=high disease activity, a value &gt;11 and &lt;=26=moderate disease activity, a value &gt;=3.4 and &lt;=11=low disease activity. Higher scores indicated higher disease activity. SDAI Remission was defined as SDAI score &lt;=3.3. Data for Core Treatment Phase from Week 0-10 is reported according to participant's re-randomization in four arms at Week 12. Data reported for Extension Phase from Week 2 to Week 24, is same data for Core Treatment Phase, but excluding participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved CDAI Remission at Each Visit Based on NRI</measure>
    <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>The CDAI was calculated from tender joint counts of 28 (score range as 0-28), swollen joint counts of 28 (score range as 0-28), participant's global assessment of disease activity (score range as 0-10), and physician global assessment of disease activity score (score range as 0-10). Total score ranged between 0-76. CDAI score of 76 or above=high disease activity, a value &gt;10 and &lt;=22=moderate disease activity, a value &gt;2.9 and &lt;=10=low disease activity. Higher scores indicated higher disease activity. CDAI Remission was defined as CDAI score &lt;=2.8. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Boolean Remission at Each Visit Based on NRI</measure>
    <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
    <description>Boolean remission criteria was defined as: tender joint count 68 &lt;=1; swollen joint count 66 &lt;=1; CRP &lt;=1 mg/dL; and disease activity assessments VAS (mm) by participants &lt;=10. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>E6011 400 mg/E6011 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the Treatment Phase (24 weeks), participants will receive E6011 400 milligrams (mg) at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E6011 400 mg/E6011 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the Treatment Phase (24 weeks), participants will receive E6011 400 mg at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/E6011 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/E6011 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E6011</intervention_name>
    <description>subcutaneous administration</description>
    <arm_group_label>E6011 400 mg/E6011 200 mg</arm_group_label>
    <arm_group_label>E6011 400 mg/E6011 400 mg</arm_group_label>
    <arm_group_label>Placebo/E6011 200 mg</arm_group_label>
    <arm_group_label>Placebo/E6011 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>subcutaneous administration</description>
    <arm_group_label>Placebo/E6011 200 mg</arm_group_label>
    <arm_group_label>Placebo/E6011 400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged ≥18 and &lt;75 years old at the time of informed consent&#xD;
&#xD;
          -  Diagnosed with rheumatoid arthritis (RA) under the 1987 American College of&#xD;
             Rheumatology (ACR) or 2010 ACR/European League Against Rheumatism (EULAR) criteria ≥12&#xD;
             weeks before informed consent&#xD;
&#xD;
          -  Received biologics treatment under approved dosage and administration for ≥12 weeks&#xD;
             but discontinued it before screening because of inadequate response&#xD;
&#xD;
          -  History of biologics treatment should be limited to 2 agents among adalimumab,&#xD;
             infliximab, golimumab, certolizumab pegol, etanercept, tocilizumab, and abatacept&#xD;
             (including biosimilars)&#xD;
&#xD;
          -  Presented ≥6 tender joints (out of 68 joints) and ≥6 swollen joints (out of 66 joints)&#xD;
             in the Screening and Observation Phases&#xD;
&#xD;
          -  Can continue stable dose regimen of methotrexate at 6 to 16 milligrams (mg)/week from&#xD;
             4 weeks before starting the study treatment until completion of the Extension Phase&#xD;
             (or until study discontinuation)&#xD;
&#xD;
          -  C-reactive protein (CRP) level ≥0.6 mg/deciliter (dL) or erythrocyte sedimentation&#xD;
             rate (ESR) ≥28 millimeters per hour (mm/hr) in the Screening Phase&#xD;
&#xD;
          -  Weighs ≥30 kilograms (kg) and ≤100 kg in the Screening Phase&#xD;
&#xD;
          -  Has voluntarily consented, in writing, to participate in this study. If a participant&#xD;
             is below the age of 20, also consented, in writing by a legally acceptable&#xD;
             representative&#xD;
&#xD;
          -  Has been thoroughly briefed on the conditions for participation in the study, is able&#xD;
             to understand, and is willing and able to comply with all aspects of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history or complication of inflammatory arthritic disorder other than RA or&#xD;
             Sjogren's syndrome&#xD;
&#xD;
          -  Meets the ACR 1991 Revised Criteria for the Classification of Global Functional Status&#xD;
             in RA Class IV in the Screening Phase&#xD;
&#xD;
          -  Received immunoglobulin preparations or blood products within 24 weeks before starting&#xD;
             the study treatment&#xD;
&#xD;
          -  Received a live vaccine within 12 weeks before starting the study treatment, or is&#xD;
             planning to receive&#xD;
&#xD;
          -  Evidence of clinically significant disease (e.g., cardiac, respiratory,&#xD;
             gastrointestinal, or renal disease) that could affect the participant's safety or&#xD;
             interfere with the study assessments in the opinion of the investigator or&#xD;
             subinvestigator&#xD;
&#xD;
          -  Complication of uncontrolled disorders such as acute cardiac infarction, unstable&#xD;
             angina, brain infarct, or symptomatic intracerebral hemorrhage&#xD;
&#xD;
          -  History of severe allergy (shock or anaphylactoid symptoms)&#xD;
&#xD;
          -  History or current clinical condition of malignant tumor, lymphoma, leukemia, or&#xD;
             lymphoproliferative disease, except for skin carcinoma (epithelial carcinoma or basal&#xD;
             cell carcinoma) and cervix carcinoma which has completely excised and without&#xD;
             metastasis or recurrence for more than 5 years before informed consent&#xD;
&#xD;
          -  Immunodeficiency or history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Infection requiring hospitalization or intravenous administration of antibiotics or&#xD;
             disease requiring administration of antivirus drugs (e.g., herpes zoster) within 4&#xD;
             weeks before starting the study treatment&#xD;
&#xD;
          -  History of tuberculosis or current complication of active tuberculosis&#xD;
&#xD;
          -  History of clinically important vasculitis&#xD;
&#xD;
          -  Tested positive for any of the following in the Screening Phase: HIV, hepatitis B&#xD;
             virus surface antigen (HBs antigen), hepatitis B virus surface antibody (HBs&#xD;
             antibody), hepatitis B virus core antibody (HBc antibody), hepatitis B virus&#xD;
             deoxyribonucleic acid (HBV DNA), hepatitis C virus antibody (HCV antibody), human&#xD;
             T-lymphotrophic virus Type I antibody (HTLV-1 antibody), or syphilis&#xD;
&#xD;
          -  Positive in tuberculosis test (QuantiFERON Tuberculosis Gold Test or T-SPOT&#xD;
             Tuberculosis Test) in the Screening Phase&#xD;
&#xD;
          -  Findings indicating a history of tuberculosis on chest x-ray in the Screening Phase&#xD;
&#xD;
          -  Neurological findings such as paralysis, visual impairment, or language disorder in&#xD;
             the Screening Phase&#xD;
&#xD;
          -  Demonstrated prolonged QTcF (Fridericia's Correction Formula) interval (&gt;450&#xD;
             milliseconds [ms]) in repeated electrocardiogram examinations&#xD;
&#xD;
          -  Females of childbearing potential who have a positive pregnancy test in the Screening&#xD;
             or Observation Phase or are breastfeeding&#xD;
&#xD;
          -  Females of childbearing potential who:&#xD;
&#xD;
               -  Had unprotected sexual intercourse within 30 days before study entry and who do&#xD;
                  not agree to use a highly effective method of contraception (e.g., total&#xD;
                  abstinence, an intrauterine device, a double-barrier method [such as condom plus&#xD;
                  diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or&#xD;
                  have a vasectomized partner with confirmed azoospermia) throughout the entire&#xD;
                  study period or for 28 days after study drug discontinuation&#xD;
&#xD;
               -  Are currently abstinent, and do not agree to use a double-barrier method (as&#xD;
                  described above) or refrain from being sexually active during the study period or&#xD;
                  for 28 days after study drug discontinuation&#xD;
&#xD;
               -  Are using hormonal contraceptives but are not on a stable dose of the same&#xD;
                  hormonal contraceptive product for at least 4 weeks before dosing and who do not&#xD;
                  agree to use the same contraceptive during the study or for 28 days after study&#xD;
                  drug discontinuation.&#xD;
&#xD;
        (NOTE: All females will be considered to be of childbearing potential unless they are&#xD;
        postmenopausal [amenorrheic for at least 12 consecutive months, in the appropriate age&#xD;
        group, and without other known or suspected cause] or have been sterilized surgically&#xD;
        [i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with&#xD;
        surgery at least 1 month before dosing]).&#xD;
&#xD;
          -  Males who have not had a successful vasectomy (confirmed azoospermia) or they and&#xD;
             their female partners do not meet the criteria above (i.e., not of childbearing&#xD;
             potential or practicing highly effective contraception throughout the study period or&#xD;
             for 28 days after study drug discontinuation). No sperm donation is allowed during the&#xD;
             study period or for 28 days after study drug discontinuation.&#xD;
&#xD;
          -  Scheduled for surgery during the study&#xD;
&#xD;
          -  Currently enrolled in another clinical study or used any investigational drug or&#xD;
             device within 28 days (or 5× the half-life, whichever is longer) before informed&#xD;
             consent&#xD;
&#xD;
          -  Has been treated with E6011 or any biologics for use in RA that has not been approved&#xD;
&#xD;
          -  Use of a psychotropic agent as recreational purpose other than therapeutic purpose&#xD;
&#xD;
          -  Any history of a medical condition or a concomitant medical condition that in the&#xD;
             opinion of the investigator or subinvestigator would compromise the participant's&#xD;
             ability to safely complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Yotsukaido</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Takasaki</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Takasaki</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #3</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kato</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Ono</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Sasebo</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Tomigusuku</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kawachinagano</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kawaguchi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Chuo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Fuchu</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Ota</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Setagaya</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Takaoka</city>
        <state>Toyama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #3</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #4</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #5</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #3</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 3, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <results_first_submitted>July 28, 2021</results_first_submitted>
  <results_first_submitted_qc>July 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2021</results_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E6011</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetmolimab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 31, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02960490/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Core and Entire Treatment Phase</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02960490/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Extension Phase</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 25, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02960490/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 46 investigative sites in Japan from 26 November 2016 to 25 November 2019.</recruitment_details>
      <pre_assignment_details>A total of 93 participants were screened, of which 66 were randomized to receive study treatment. This study has a Core Treatment Phase (Treatment Phase: 12 Weeks; Entire Treatment Phase [Re-randomized Participants]: 12 Weeks) and an Extension Phase: 80 Weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Core Treatment Phase: Placebo</title>
          <description>During the Core Treatment Phase, participants received E6011-matched placebo, infusion, subcutaneously, at Weeks 0, 1, and 2 and then every 2 weeks up to Week 10.</description>
        </group>
        <group group_id="P2">
          <title>Core Treatment Phase: E6011 400 mg</title>
          <description>During the Core Treatment Phase, participants received E6011 400 milligram (mg), infusion, subcutaneously, at Weeks 0, 1, and 2 and then every 2 weeks up to Week 10.</description>
        </group>
        <group group_id="P3">
          <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
          <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
        </group>
        <group group_id="P4">
          <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
          <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
        </group>
        <group group_id="P5">
          <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
          <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
        </group>
        <group group_id="P6">
          <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
          <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
        </group>
        <group group_id="P7">
          <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
          <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
        </group>
        <group group_id="P8">
          <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
          <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
        </group>
        <group group_id="P9">
          <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
          <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
        </group>
        <group group_id="P10">
          <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
          <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Phase(Double-blind): 12 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set (SAS)</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Re-randomized Participants: 12 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>FAS</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>SAS</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Phase(Open-label): 80 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="13"/>
                <participants group_id="P8" count="11">One Participant who completed Core Treatment Phase (Placebo Then E6011 400 mg arm) had inadequate therapeutic effect at Week 24, hence did not started Extension phase.</participants>
                <participants group_id="P9" count="13"/>
                <participants group_id="P10" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="13"/>
                <participants group_id="P8" count="11"/>
                <participants group_id="P9" count="13"/>
                <participants group_id="P10" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>FAS</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="13"/>
                <participants group_id="P8" count="11"/>
                <participants group_id="P9" count="13"/>
                <participants group_id="P10" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>SAS</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="13"/>
                <participants group_id="P8" count="11"/>
                <participants group_id="P9" count="13"/>
                <participants group_id="P10" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="9"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The FAS was the group of randomized participants who received at least 1 dose of study drug and had at least 1 postdose primary efficacy measurement.</population>
      <group_list>
        <group group_id="B1">
          <title>Core Treatment Phase: Placebo</title>
          <description>During the Core Treatment Phase, participants received E6011-matched placebo, infusion, subcutaneously, at Weeks 0, 1, and 2 and then every 2 weeks up to Week 10. Participants who continued the study beyond Week 12 in the Core Treatment Phase (Placebo) received E6011 200 mg or 400 mg, infusion, subcutaneously every 2 weeks between weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
        </group>
        <group group_id="B2">
          <title>Core Treatment Phase: E6011 400 mg</title>
          <description>During the Core Treatment Phase, participants received E6011 400 mg, infusion, subcutaneously, at Weeks 0, 1, and 2 and then every 2 weeks up to Week 10. Participants who continued the study beyond Week 12 in the Core Treatment Phase (E6011 400 mg) received E6011 200 mg or 400 mg, infusion, subcutaneously every 2 weeks between weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="10.64"/>
                    <measurement group_id="B2" value="53.5" spread="11.30"/>
                    <measurement group_id="B3" value="51.5" spread="11.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Core Treatment Phase: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 12 Based on Non-responder Imputation (NRI)</title>
        <description>The ACR20 response was defined as if the following 3 criteria (ACR components) were met: Greater than or equal to (&gt;=) 20 percent (%) reduction from baseline in the tender joint count (TJC) in 68 joints (TJC68); &gt;=20% reduction from baseline in the swollen joint count (SJC) in 66 joints (SJC66); &gt;=20% reduction from baseline in at least 3 of the following 5 assessments: Physician's Global Assessment of Disease Activity (visual analog scale [VAS]), Participant's Global Assessment of Disease Activity (VAS), Participant's Assessment of Pain (VAS), Health Assessment Questionnaire disability index (HAQ-DI), and C-reactive protein (CRP).</description>
        <time_frame>Week 12</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose primary efficacy measurement. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo</title>
            <description>During the Core Treatment Phase, participants received E6011-matched placebo, infusion, subcutaneously, at Weeks 0, 1, and 2 and then every 2 weeks up to Week 10.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: E6011 400 mg</title>
            <description>During the Core Treatment Phase, participants received E6011 400 mg, infusion, subcutaneously, at Weeks 0, 1, and 2 and then every 2 weeks up to Week 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Treatment Phase: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 12 Based on Non-responder Imputation (NRI)</title>
          <description>The ACR20 response was defined as if the following 3 criteria (ACR components) were met: Greater than or equal to (&gt;=) 20 percent (%) reduction from baseline in the tender joint count (TJC) in 68 joints (TJC68); &gt;=20% reduction from baseline in the swollen joint count (SJC) in 66 joints (SJC66); &gt;=20% reduction from baseline in at least 3 of the following 5 assessments: Physician's Global Assessment of Disease Activity (visual analog scale [VAS]), Participant's Global Assessment of Disease Activity (VAS), Participant's Assessment of Pain (VAS), Health Assessment Questionnaire disability index (HAQ-DI), and C-reactive protein (CRP).</description>
          <population>FAS included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose primary efficacy measurement. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" lower_limit="12.08" upper_limit="42.47"/>
                    <measurement group_id="O2" value="22.6" lower_limit="7.86" upper_limit="37.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.621</p_value>
            <method>Regression, Logistic</method>
            <param_type>Difference from Placebo</param_type>
            <param_value>-4.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.85</ci_lower_limit>
            <ci_upper_limit>16.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an ACR20 Response at Weeks 2, 4, 8, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72 Based on NRI</title>
        <description>The ACR20 response was defined as if the following 3 criteria (ACR components) were met: &gt;=20% reduction from baseline in the TJC in 68 joints (TJC68); &gt;=20% reduction from baseline in the SJC in 66 joints (SJC66); &gt;=20% reduction from baseline in at least 3 of the following 5 assessments: Physician's Global Assessment of Disease Activity (VAS), Participant's Global Assessment of Disease Activity (VAS), Participant's Assessment of Pain (VAS), HAQ-DI, and CRP. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 16, 20, 24; Extension Phase: Weeks 2, 4, 8, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an ACR20 Response at Weeks 2, 4, 8, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72 Based on NRI</title>
          <description>The ACR20 response was defined as if the following 3 criteria (ACR components) were met: &gt;=20% reduction from baseline in the TJC in 68 joints (TJC68); &gt;=20% reduction from baseline in the SJC in 66 joints (SJC66); &gt;=20% reduction from baseline in at least 3 of the following 5 assessments: Physician's Global Assessment of Disease Activity (VAS), Participant's Global Assessment of Disease Activity (VAS), Participant's Assessment of Pain (VAS), HAQ-DI, and CRP. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="0.00" upper_limit="30.54"/>
                    <measurement group_id="O2" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="25.0" lower_limit="0.50" upper_limit="49.50"/>
                    <measurement group_id="O5" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="20.0" lower_limit="0.00" upper_limit="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="0.00" upper_limit="30.54"/>
                    <measurement group_id="O2" value="28.6" lower_limit="4.91" upper_limit="52.24"/>
                    <measurement group_id="O3" value="28.6" lower_limit="4.91" upper_limit="52.24"/>
                    <measurement group_id="O4" value="8.3" lower_limit="0.00" upper_limit="23.97"/>
                    <measurement group_id="O5" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O6" value="27.3" lower_limit="0.95" upper_limit="53.59"/>
                    <measurement group_id="O7" value="30.8" lower_limit="5.68" upper_limit="55.86"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="0.00" upper_limit="40.24"/>
                    <measurement group_id="O2" value="28.6" lower_limit="4.91" upper_limit="52.24"/>
                    <measurement group_id="O3" value="35.7" lower_limit="10.61" upper_limit="60.81"/>
                    <measurement group_id="O4" value="25.0" lower_limit="0.50" upper_limit="49.50"/>
                    <measurement group_id="O5" value="23.1" lower_limit="0.17" upper_limit="45.98"/>
                    <measurement group_id="O6" value="27.3" lower_limit="0.95" upper_limit="53.59"/>
                    <measurement group_id="O7" value="38.5" lower_limit="12.02" upper_limit="64.91"/>
                    <measurement group_id="O8" value="30.0" lower_limit="1.60" upper_limit="58.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" lower_limit="4.29" upper_limit="49.05"/>
                    <measurement group_id="O2" value="28.6" lower_limit="4.91" upper_limit="52.24"/>
                    <measurement group_id="O3" value="42.9" lower_limit="16.93" upper_limit="68.78"/>
                    <measurement group_id="O4" value="50.0" lower_limit="21.71" upper_limit="78.29"/>
                    <measurement group_id="O5" value="30.8" lower_limit="5.68" upper_limit="55.86"/>
                    <measurement group_id="O6" value="36.4" lower_limit="7.94" upper_limit="64.79"/>
                    <measurement group_id="O7" value="46.2" lower_limit="19.05" upper_limit="73.25"/>
                    <measurement group_id="O8" value="60.0" lower_limit="29.64" upper_limit="90.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" lower_limit="21.42" upper_limit="71.91"/>
                    <measurement group_id="O2" value="35.7" lower_limit="10.61" upper_limit="60.81"/>
                    <measurement group_id="O3" value="28.6" lower_limit="4.91" upper_limit="52.24"/>
                    <measurement group_id="O4" value="50.0" lower_limit="21.71" upper_limit="78.29"/>
                    <measurement group_id="O5" value="53.8" lower_limit="26.75" upper_limit="80.95"/>
                    <measurement group_id="O6" value="45.5" lower_limit="16.03" upper_limit="74.88"/>
                    <measurement group_id="O7" value="30.8" lower_limit="5.68" upper_limit="55.86"/>
                    <measurement group_id="O8" value="50.0" lower_limit="19.01" upper_limit="80.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" lower_limit="21.42" upper_limit="71.91"/>
                    <measurement group_id="O2" value="28.6" lower_limit="4.91" upper_limit="52.24"/>
                    <measurement group_id="O3" value="21.4" lower_limit="0.00" upper_limit="42.92"/>
                    <measurement group_id="O4" value="33.3" lower_limit="6.66" upper_limit="60.01"/>
                    <measurement group_id="O5" value="53.8" lower_limit="26.75" upper_limit="80.95"/>
                    <measurement group_id="O6" value="36.4" lower_limit="7.94" upper_limit="64.79"/>
                    <measurement group_id="O7" value="23.1" lower_limit="0.17" upper_limit="45.98"/>
                    <measurement group_id="O8" value="30.0" lower_limit="1.60" upper_limit="58.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="53.8" lower_limit="26.75" upper_limit="80.95"/>
                    <measurement group_id="O6" value="54.5" lower_limit="25.12" upper_limit="83.97"/>
                    <measurement group_id="O7" value="38.5" lower_limit="12.02" upper_limit="64.91"/>
                    <measurement group_id="O8" value="50.0" lower_limit="19.01" upper_limit="80.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="61.5" lower_limit="35.09" upper_limit="87.98"/>
                    <measurement group_id="O6" value="36.4" lower_limit="7.94" upper_limit="64.79"/>
                    <measurement group_id="O7" value="38.5" lower_limit="12.02" upper_limit="64.91"/>
                    <measurement group_id="O8" value="50.0" lower_limit="19.01" upper_limit="80.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="46.2" lower_limit="19.05" upper_limit="73.25"/>
                    <measurement group_id="O6" value="36.4" lower_limit="7.94" upper_limit="64.79"/>
                    <measurement group_id="O7" value="38.5" lower_limit="12.02" upper_limit="64.91"/>
                    <measurement group_id="O8" value="50.0" lower_limit="19.01" upper_limit="80.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="61.5" lower_limit="35.09" upper_limit="87.98"/>
                    <measurement group_id="O6" value="36.4" lower_limit="7.94" upper_limit="64.79"/>
                    <measurement group_id="O7" value="30.8" lower_limit="5.68" upper_limit="55.86"/>
                    <measurement group_id="O8" value="40.0" lower_limit="9.64" upper_limit="70.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="61.5" lower_limit="35.09" upper_limit="87.98"/>
                    <measurement group_id="O6" value="45.5" lower_limit="16.03" upper_limit="74.88"/>
                    <measurement group_id="O7" value="38.5" lower_limit="12.02" upper_limit="64.91"/>
                    <measurement group_id="O8" value="40.0" lower_limit="9.64" upper_limit="70.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="53.8" lower_limit="26.75" upper_limit="80.95"/>
                    <measurement group_id="O6" value="54.5" lower_limit="25.12" upper_limit="83.97"/>
                    <measurement group_id="O7" value="53.8" lower_limit="26.75" upper_limit="80.95"/>
                    <measurement group_id="O8" value="40.0" lower_limit="9.64" upper_limit="70.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="38.5" lower_limit="12.02" upper_limit="64.91"/>
                    <measurement group_id="O6" value="45.5" lower_limit="16.03" upper_limit="74.88"/>
                    <measurement group_id="O7" value="53.8" lower_limit="26.75" upper_limit="80.95"/>
                    <measurement group_id="O8" value="50.0" lower_limit="19.01" upper_limit="80.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="53.8" lower_limit="26.75" upper_limit="80.95"/>
                    <measurement group_id="O6" value="27.3" lower_limit="0.95" upper_limit="53.59"/>
                    <measurement group_id="O7" value="38.5" lower_limit="12.02" upper_limit="64.91"/>
                    <measurement group_id="O8" value="20.0" lower_limit="0.00" upper_limit="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="46.2" lower_limit="19.05" upper_limit="73.25"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="38.5" lower_limit="12.02" upper_limit="64.91"/>
                    <measurement group_id="O8" value="30.0" lower_limit="1.60" upper_limit="58.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="46.2" lower_limit="19.05" upper_limit="73.25"/>
                    <measurement group_id="O6" value="27.3" lower_limit="0.95" upper_limit="53.59"/>
                    <measurement group_id="O7" value="46.2" lower_limit="19.05" upper_limit="73.25"/>
                    <measurement group_id="O8" value="20.0" lower_limit="0.00" upper_limit="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="38.5" lower_limit="12.02" upper_limit="64.91"/>
                    <measurement group_id="O6" value="27.3" lower_limit="0.95" upper_limit="53.59"/>
                    <measurement group_id="O7" value="38.5" lower_limit="12.02" upper_limit="64.91"/>
                    <measurement group_id="O8" value="20.0" lower_limit="0.00" upper_limit="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="38.5" lower_limit="12.02" upper_limit="64.91"/>
                    <measurement group_id="O6" value="45.5" lower_limit="16.03" upper_limit="74.88"/>
                    <measurement group_id="O7" value="53.8" lower_limit="26.75" upper_limit="80.95"/>
                    <measurement group_id="O8" value="20.0" lower_limit="0.00" upper_limit="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an ACR50 Response at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72 Based on NRI</title>
        <description>The ACR50 response was defined as if the following 3 criteria (ACR components) were met: &gt;=50% reduction from baseline in the TJC in 68 joints (TJC68); &gt;=50% reduction from baseline in the SJC in 66 joints (SJC66); &gt;=50% reduction from baseline in at least 3 of the following 5 assessments: Physician's Global Assessment of Disease Activity (VAS), Participant's Global Assessment of Disease Activity (VAS), Participant's Assessment of Pain (VAS), HAQ-DI, and CRP. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an ACR50 Response at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72 Based on NRI</title>
          <description>The ACR50 response was defined as if the following 3 criteria (ACR components) were met: &gt;=50% reduction from baseline in the TJC in 68 joints (TJC68); &gt;=50% reduction from baseline in the SJC in 66 joints (SJC66); &gt;=50% reduction from baseline in at least 3 of the following 5 assessments: Physician's Global Assessment of Disease Activity (VAS), Participant's Global Assessment of Disease Activity (VAS), Participant's Assessment of Pain (VAS), HAQ-DI, and CRP. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="14.3" lower_limit="0.00" upper_limit="32.62"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="14.3" lower_limit="0.00" upper_limit="32.62"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="16.7" lower_limit="0.00" upper_limit="37.75"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="20.0" lower_limit="0.00" upper_limit="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="16.7" lower_limit="0.00" upper_limit="37.75"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="20.0" lower_limit="0.00" upper_limit="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="0.00" upper_limit="40.24"/>
                    <measurement group_id="O2" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="16.7" lower_limit="0.00" upper_limit="37.75"/>
                    <measurement group_id="O5" value="23.1" lower_limit="0.17" upper_limit="45.98"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="20.0" lower_limit="0.00" upper_limit="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="0.00" upper_limit="40.24"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="16.7" lower_limit="0.00" upper_limit="37.75"/>
                    <measurement group_id="O5" value="23.1" lower_limit="0.17" upper_limit="45.98"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="20.0" lower_limit="0.00" upper_limit="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="30.8" lower_limit="5.68" upper_limit="55.86"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="30.0" lower_limit="1.60" upper_limit="58.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="30.8" lower_limit="5.68" upper_limit="55.86"/>
                    <measurement group_id="O8" value="20.0" lower_limit="0.00" upper_limit="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="23.1" lower_limit="0.17" upper_limit="45.98"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="23.1" lower_limit="0.17" upper_limit="45.98"/>
                    <measurement group_id="O8" value="20.0" lower_limit="0.00" upper_limit="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="30.8" lower_limit="5.68" upper_limit="55.86"/>
                    <measurement group_id="O6" value="27.3" lower_limit="0.95" upper_limit="53.59"/>
                    <measurement group_id="O7" value="23.1" lower_limit="0.17" upper_limit="45.98"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="23.1" lower_limit="0.17" upper_limit="45.98"/>
                    <measurement group_id="O6" value="27.3" lower_limit="0.95" upper_limit="53.59"/>
                    <measurement group_id="O7" value="30.8" lower_limit="5.68" upper_limit="55.86"/>
                    <measurement group_id="O8" value="20.0" lower_limit="0.00" upper_limit="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O6" value="27.3" lower_limit="0.95" upper_limit="53.59"/>
                    <measurement group_id="O7" value="30.8" lower_limit="5.68" upper_limit="55.86"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="23.1" lower_limit="0.17" upper_limit="45.98"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="23.1" lower_limit="0.17" upper_limit="45.98"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="30.8" lower_limit="5.68" upper_limit="55.86"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="30.8" lower_limit="5.68" upper_limit="55.86"/>
                    <measurement group_id="O8" value="20.0" lower_limit="0.00" upper_limit="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="23.1" lower_limit="0.17" upper_limit="45.98"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="23.1" lower_limit="0.17" upper_limit="45.98"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="23.1" lower_limit="0.17" upper_limit="45.98"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="23.1" lower_limit="0.17" upper_limit="45.98"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O6" value="27.3" lower_limit="0.95" upper_limit="53.59"/>
                    <measurement group_id="O7" value="30.8" lower_limit="5.68" upper_limit="55.86"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an ACR70 Response at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72 Based on NRI</title>
        <description>The ACR70 response was defined as if the following 3 criteria (ACR components) were met: &gt;=70% reduction from baseline in the TJC in 68 joints (TJC68); &gt;=70% reduction from baseline in the SJC in 66 joints (SJC66); &gt;=70% reduction from baseline in at least 3 of the following 5 assessments: Physician's Global Assessment of Disease Activity (VAS), Participant's Global Assessment of Disease Activity (VAS), Participant's Assessment of Pain (VAS), HAQ-DI, and CRP. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an ACR70 Response at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72 Based on NRI</title>
          <description>The ACR70 response was defined as if the following 3 criteria (ACR components) were met: &gt;=70% reduction from baseline in the TJC in 68 joints (TJC68); &gt;=70% reduction from baseline in the SJC in 66 joints (SJC66); &gt;=70% reduction from baseline in at least 3 of the following 5 assessments: Physician's Global Assessment of Disease Activity (VAS), Participant's Global Assessment of Disease Activity (VAS), Participant's Assessment of Pain (VAS), HAQ-DI, and CRP. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="8.3" lower_limit="0.00" upper_limit="23.97"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tender Joint Counts (TJC) at Each Visit Based on Last Observation Carried Forward (LOCF)</title>
        <description>A total of 28 joints were examined for tenderness by applying pressure to the joint line or by moving joints through their respective ranges of motion. Joints were examined for tenderness by applying pressure to the joint line or by moving joints through their respective ranges of motion. Tender joints were marked with tick or cross in corresponding frames of the Assessment Sheet for Tender Joint Counts. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tender Joint Counts (TJC) at Each Visit Based on Last Observation Carried Forward (LOCF)</title>
          <description>A total of 28 joints were examined for tenderness by applying pressure to the joint line or by moving joints through their respective ranges of motion. Joints were examined for tenderness by applying pressure to the joint line or by moving joints through their respective ranges of motion. Tender joints were marked with tick or cross in corresponding frames of the Assessment Sheet for Tender Joint Counts. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="6.88"/>
                    <measurement group_id="O2" value="11.7" spread="7.74"/>
                    <measurement group_id="O3" value="9.9" spread="4.80"/>
                    <measurement group_id="O4" value="12.8" spread="7.58"/>
                    <measurement group_id="O5" value="8.7" spread="4.85"/>
                    <measurement group_id="O6" value="11.6" spread="8.67"/>
                    <measurement group_id="O7" value="9.5" spread="4.75"/>
                    <measurement group_id="O8" value="10.3" spread="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="3.92"/>
                    <measurement group_id="O2" value="-1.3" spread="3.41"/>
                    <measurement group_id="O3" value="-1.9" spread="4.48"/>
                    <measurement group_id="O4" value="-4.4" spread="5.52"/>
                    <measurement group_id="O5" value="-2.0" spread="4.06"/>
                    <measurement group_id="O6" value="-1.3" spread="3.77"/>
                    <measurement group_id="O7" value="-2.0" spread="4.65"/>
                    <measurement group_id="O8" value="-3.0" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="6.07"/>
                    <measurement group_id="O2" value="-2.9" spread="5.11"/>
                    <measurement group_id="O3" value="-2.3" spread="5.81"/>
                    <measurement group_id="O4" value="-5.1" spread="6.16"/>
                    <measurement group_id="O5" value="-3.2" spread="6.48"/>
                    <measurement group_id="O6" value="-3.1" spread="5.74"/>
                    <measurement group_id="O7" value="-1.8" spread="5.80"/>
                    <measurement group_id="O8" value="-3.9" spread="5.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="5.51"/>
                    <measurement group_id="O2" value="-2.9" spread="8.89"/>
                    <measurement group_id="O3" value="-1.9" spread="6.18"/>
                    <measurement group_id="O4" value="-5.8" spread="3.05"/>
                    <measurement group_id="O5" value="-3.5" spread="5.91"/>
                    <measurement group_id="O6" value="-3.8" spread="9.72"/>
                    <measurement group_id="O7" value="-1.3" spread="6.06"/>
                    <measurement group_id="O8" value="-5.2" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="5.59"/>
                    <measurement group_id="O2" value="-2.1" spread="8.75"/>
                    <measurement group_id="O3" value="-2.0" spread="6.11"/>
                    <measurement group_id="O4" value="-6.2" spread="3.86"/>
                    <measurement group_id="O5" value="-3.1" spread="5.92"/>
                    <measurement group_id="O6" value="-3.5" spread="9.05"/>
                    <measurement group_id="O7" value="-1.8" spread="6.30"/>
                    <measurement group_id="O8" value="-6.1" spread="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="6.65"/>
                    <measurement group_id="O2" value="-4.1" spread="5.17"/>
                    <measurement group_id="O3" value="-2.9" spread="5.73"/>
                    <measurement group_id="O4" value="-7.5" spread="6.97"/>
                    <measurement group_id="O5" value="-4.5" spread="7.15"/>
                    <measurement group_id="O6" value="-4.8" spread="5.38"/>
                    <measurement group_id="O7" value="-2.6" spread="5.84"/>
                    <measurement group_id="O8" value="-6.5" spread="5.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="6.06"/>
                    <measurement group_id="O2" value="-4.1" spread="7.19"/>
                    <measurement group_id="O3" value="-2.9" spread="6.46"/>
                    <measurement group_id="O4" value="-8.2" spread="7.30"/>
                    <measurement group_id="O5" value="-5.2" spread="6.48"/>
                    <measurement group_id="O6" value="-4.9" spread="7.82"/>
                    <measurement group_id="O7" value="-2.8" spread="6.72"/>
                    <measurement group_id="O8" value="-6.3" spread="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="5.63"/>
                    <measurement group_id="O2" value="-3.7" spread="8.30"/>
                    <measurement group_id="O3" value="-2.6" spread="6.06"/>
                    <measurement group_id="O4" value="-7.8" spread="8.07"/>
                    <measurement group_id="O5" value="-5.5" spread="5.99"/>
                    <measurement group_id="O6" value="-3.9" spread="9.81"/>
                    <measurement group_id="O7" value="-2.5" spread="6.29"/>
                    <measurement group_id="O8" value="-6.2" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-4.6" spread="6.64"/>
                    <measurement group_id="O6" value="-4.5" spread="10.32"/>
                    <measurement group_id="O7" value="-2.4" spread="7.54"/>
                    <measurement group_id="O8" value="-4.7" spread="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-3.7" spread="7.16"/>
                    <measurement group_id="O6" value="-3.9" spread="9.08"/>
                    <measurement group_id="O7" value="-3.5" spread="8.42"/>
                    <measurement group_id="O8" value="-5.3" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-4.7" spread="7.04"/>
                    <measurement group_id="O6" value="-5.0" spread="8.93"/>
                    <measurement group_id="O7" value="-3.5" spread="7.61"/>
                    <measurement group_id="O8" value="-4.5" spread="8.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-3.8" spread="7.16"/>
                    <measurement group_id="O6" value="-5.1" spread="8.56"/>
                    <measurement group_id="O7" value="-3.2" spread="7.72"/>
                    <measurement group_id="O8" value="-4.1" spread="6.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-4.5" spread="7.17"/>
                    <measurement group_id="O6" value="-5.5" spread="8.99"/>
                    <measurement group_id="O7" value="-3.6" spread="7.89"/>
                    <measurement group_id="O8" value="-4.4" spread="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-4.2" spread="7.32"/>
                    <measurement group_id="O6" value="-5.5" spread="9.37"/>
                    <measurement group_id="O7" value="-2.9" spread="7.71"/>
                    <measurement group_id="O8" value="-2.9" spread="6.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-2.5" spread="6.83"/>
                    <measurement group_id="O6" value="-5.8" spread="9.90"/>
                    <measurement group_id="O7" value="-3.8" spread="7.93"/>
                    <measurement group_id="O8" value="-4.9" spread="6.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-2.8" spread="6.88"/>
                    <measurement group_id="O6" value="-6.3" spread="10.25"/>
                    <measurement group_id="O7" value="-2.8" spread="8.00"/>
                    <measurement group_id="O8" value="-4.5" spread="7.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-2.8" spread="6.80"/>
                    <measurement group_id="O6" value="-4.5" spread="7.33"/>
                    <measurement group_id="O7" value="-3.5" spread="8.12"/>
                    <measurement group_id="O8" value="-4.5" spread="7.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-2.6" spread="6.79"/>
                    <measurement group_id="O6" value="-2.6" spread="6.41"/>
                    <measurement group_id="O7" value="-4.1" spread="8.27"/>
                    <measurement group_id="O8" value="-4.4" spread="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-2.8" spread="6.72"/>
                    <measurement group_id="O6" value="-4.6" spread="8.03"/>
                    <measurement group_id="O7" value="-2.9" spread="8.20"/>
                    <measurement group_id="O8" value="-4.1" spread="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-2.8" spread="6.65"/>
                    <measurement group_id="O6" value="-5.5" spread="9.03"/>
                    <measurement group_id="O7" value="-3.5" spread="8.33"/>
                    <measurement group_id="O8" value="-4.1" spread="7.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Swollen Joint Counts (SJC) at Each Visit Based on LOCF</title>
        <description>A total of 28 joints were examined for swollen joints. Swollen joints were marked with open circles in corresponding frames of the Assessment Sheet for Swollen Joint Counts. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Swollen Joint Counts (SJC) at Each Visit Based on LOCF</title>
          <description>A total of 28 joints were examined for swollen joints. Swollen joints were marked with open circles in corresponding frames of the Assessment Sheet for Swollen Joint Counts. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="2.91"/>
                    <measurement group_id="O2" value="9.5" spread="6.14"/>
                    <measurement group_id="O3" value="8.9" spread="3.47"/>
                    <measurement group_id="O4" value="8.8" spread="4.39"/>
                    <measurement group_id="O5" value="7.0" spread="2.97"/>
                    <measurement group_id="O6" value="9.5" spread="6.98"/>
                    <measurement group_id="O7" value="9.2" spread="3.51"/>
                    <measurement group_id="O8" value="7.6" spread="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="2.99"/>
                    <measurement group_id="O2" value="-2.6" spread="2.31"/>
                    <measurement group_id="O3" value="-2.0" spread="2.86"/>
                    <measurement group_id="O4" value="-3.3" spread="4.69"/>
                    <measurement group_id="O5" value="-2.7" spread="3.17"/>
                    <measurement group_id="O6" value="-2.7" spread="2.57"/>
                    <measurement group_id="O7" value="-2.2" spread="2.91"/>
                    <measurement group_id="O8" value="-2.6" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="3.73"/>
                    <measurement group_id="O2" value="-3.7" spread="3.95"/>
                    <measurement group_id="O3" value="-1.8" spread="3.60"/>
                    <measurement group_id="O4" value="-3.9" spread="4.14"/>
                    <measurement group_id="O5" value="-2.4" spread="3.75"/>
                    <measurement group_id="O6" value="-3.5" spread="4.44"/>
                    <measurement group_id="O7" value="-1.9" spread="3.71"/>
                    <measurement group_id="O8" value="-3.9" spread="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="3.33"/>
                    <measurement group_id="O2" value="-4.8" spread="6.38"/>
                    <measurement group_id="O3" value="-0.8" spread="4.54"/>
                    <measurement group_id="O4" value="-4.8" spread="4.15"/>
                    <measurement group_id="O5" value="-3.5" spread="3.33"/>
                    <measurement group_id="O6" value="-5.1" spread="7.20"/>
                    <measurement group_id="O7" value="-0.8" spread="4.72"/>
                    <measurement group_id="O8" value="-5.0" spread="4.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="3.95"/>
                    <measurement group_id="O2" value="-4.2" spread="6.40"/>
                    <measurement group_id="O3" value="-2.5" spread="4.01"/>
                    <measurement group_id="O4" value="-4.3" spread="4.61"/>
                    <measurement group_id="O5" value="-3.5" spread="3.95"/>
                    <measurement group_id="O6" value="-4.5" spread="7.22"/>
                    <measurement group_id="O7" value="-2.8" spread="4.04"/>
                    <measurement group_id="O8" value="-4.2" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="4.06"/>
                    <measurement group_id="O2" value="-5.4" spread="5.45"/>
                    <measurement group_id="O3" value="-1.9" spread="4.57"/>
                    <measurement group_id="O4" value="-5.3" spread="4.63"/>
                    <measurement group_id="O5" value="-3.5" spread="3.95"/>
                    <measurement group_id="O6" value="-5.6" spread="6.17"/>
                    <measurement group_id="O7" value="-1.9" spread="4.75"/>
                    <measurement group_id="O8" value="-5.1" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="4.60"/>
                    <measurement group_id="O2" value="-5.8" spread="6.10"/>
                    <measurement group_id="O3" value="-1.4" spread="4.82"/>
                    <measurement group_id="O4" value="-5.8" spread="4.34"/>
                    <measurement group_id="O5" value="-3.2" spread="4.76"/>
                    <measurement group_id="O6" value="-6.0" spread="6.65"/>
                    <measurement group_id="O7" value="-1.4" spread="4.82"/>
                    <measurement group_id="O8" value="-5.5" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="4.45"/>
                    <measurement group_id="O2" value="-5.4" spread="7.26"/>
                    <measurement group_id="O3" value="-0.6" spread="5.65"/>
                    <measurement group_id="O4" value="-4.0" spread="3.79"/>
                    <measurement group_id="O5" value="-4.4" spread="4.33"/>
                    <measurement group_id="O6" value="-4.9" spread="8.97"/>
                    <measurement group_id="O7" value="-0.8" spread="5.83"/>
                    <measurement group_id="O8" value="-4.1" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-4.1" spread="3.95"/>
                    <measurement group_id="O6" value="-5.6" spread="7.85"/>
                    <measurement group_id="O7" value="-1.1" spread="5.63"/>
                    <measurement group_id="O8" value="-4.6" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-3.7" spread="3.43"/>
                    <measurement group_id="O6" value="-5.3" spread="7.99"/>
                    <measurement group_id="O7" value="-1.1" spread="6.50"/>
                    <measurement group_id="O8" value="-4.5" spread="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-3.7" spread="3.75"/>
                    <measurement group_id="O6" value="-5.7" spread="7.67"/>
                    <measurement group_id="O7" value="-1.2" spread="6.95"/>
                    <measurement group_id="O8" value="-3.7" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-3.5" spread="3.64"/>
                    <measurement group_id="O6" value="-5.5" spread="7.94"/>
                    <measurement group_id="O7" value="-2.8" spread="7.01"/>
                    <measurement group_id="O8" value="-3.8" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-2.5" spread="6.65"/>
                    <measurement group_id="O6" value="-5.6" spread="7.84"/>
                    <measurement group_id="O7" value="-1.8" spread="7.00"/>
                    <measurement group_id="O8" value="-2.8" spread="6.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-3.5" spread="3.41"/>
                    <measurement group_id="O6" value="-5.5" spread="8.18"/>
                    <measurement group_id="O7" value="-2.0" spread="6.43"/>
                    <measurement group_id="O8" value="-3.1" spread="5.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-2.4" spread="4.03"/>
                    <measurement group_id="O6" value="-4.9" spread="8.58"/>
                    <measurement group_id="O7" value="-1.5" spread="6.57"/>
                    <measurement group_id="O8" value="-4.3" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-2.8" spread="4.12"/>
                    <measurement group_id="O6" value="-5.1" spread="8.70"/>
                    <measurement group_id="O7" value="-2.1" spread="6.51"/>
                    <measurement group_id="O8" value="-3.7" spread="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-2.8" spread="4.16"/>
                    <measurement group_id="O6" value="-4.3" spread="7.93"/>
                    <measurement group_id="O7" value="-2.7" spread="7.25"/>
                    <measurement group_id="O8" value="-4.1" spread="6.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-2.5" spread="3.93"/>
                    <measurement group_id="O6" value="-4.0" spread="7.89"/>
                    <measurement group_id="O7" value="-1.8" spread="7.56"/>
                    <measurement group_id="O8" value="-3.6" spread="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-2.8" spread="4.13"/>
                    <measurement group_id="O6" value="-4.0" spread="8.31"/>
                    <measurement group_id="O7" value="-1.6" spread="6.95"/>
                    <measurement group_id="O8" value="-3.4" spread="6.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-2.7" spread="4.03"/>
                    <measurement group_id="O6" value="-4.5" spread="9.11"/>
                    <measurement group_id="O7" value="-2.6" spread="7.31"/>
                    <measurement group_id="O8" value="-3.1" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Participant's Assessment of Pain Based on VAS Score at Each Visit Based on LOCF</title>
        <description>Intensity and severity of pain associated with rheumatoid arthritis (RA) were indicated by the participant on a score sheet, Pain/disease activity assessments reported by the participant, by placing a mark on a 100 millimeter (mm) horizontal VAS. Pain assessments reported by the participant, by placing a mark on a 100 mm horizontal VAS. The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity). Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant's Assessment of Pain Based on VAS Score at Each Visit Based on LOCF</title>
          <description>Intensity and severity of pain associated with rheumatoid arthritis (RA) were indicated by the participant on a score sheet, Pain/disease activity assessments reported by the participant, by placing a mark on a 100 millimeter (mm) horizontal VAS. Pain assessments reported by the participant, by placing a mark on a 100 mm horizontal VAS. The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity). Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7" spread="32.02"/>
                    <measurement group_id="O2" value="55.9" spread="30.33"/>
                    <measurement group_id="O3" value="56.9" spread="33.07"/>
                    <measurement group_id="O4" value="60.3" spread="20.78"/>
                    <measurement group_id="O5" value="57.5" spread="28.43"/>
                    <measurement group_id="O6" value="52.5" spread="29.96"/>
                    <measurement group_id="O7" value="54.2" spread="32.67"/>
                    <measurement group_id="O8" value="56.4" spread="18.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="15.50"/>
                    <measurement group_id="O2" value="-3.3" spread="15.47"/>
                    <measurement group_id="O3" value="-3.3" spread="22.53"/>
                    <measurement group_id="O4" value="-4.8" spread="19.07"/>
                    <measurement group_id="O5" value="-7.4" spread="15.71"/>
                    <measurement group_id="O6" value="-3.4" spread="17.57"/>
                    <measurement group_id="O7" value="-3.0" spread="23.42"/>
                    <measurement group_id="O8" value="-1.9" spread="19.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="16.50"/>
                    <measurement group_id="O2" value="-13.4" spread="26.58"/>
                    <measurement group_id="O3" value="-8.4" spread="21.23"/>
                    <measurement group_id="O4" value="-6.3" spread="17.61"/>
                    <measurement group_id="O5" value="-11.2" spread="17.32"/>
                    <measurement group_id="O6" value="-12.0" spread="27.40"/>
                    <measurement group_id="O7" value="-7.5" spread="21.82"/>
                    <measurement group_id="O8" value="-8.8" spread="18.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.9" spread="18.95"/>
                    <measurement group_id="O2" value="-14.2" spread="30.92"/>
                    <measurement group_id="O3" value="-9.6" spread="21.94"/>
                    <measurement group_id="O4" value="-12.6" spread="14.88"/>
                    <measurement group_id="O5" value="-14.7" spread="19.04"/>
                    <measurement group_id="O6" value="-12.8" spread="34.33"/>
                    <measurement group_id="O7" value="-7.5" spread="21.19"/>
                    <measurement group_id="O8" value="-14.1" spread="15.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="25.01"/>
                    <measurement group_id="O2" value="-8.0" spread="24.10"/>
                    <measurement group_id="O3" value="-15.1" spread="18.89"/>
                    <measurement group_id="O4" value="-16.8" spread="20.23"/>
                    <measurement group_id="O5" value="-9.5" spread="23.09"/>
                    <measurement group_id="O6" value="-7.6" spread="26.27"/>
                    <measurement group_id="O7" value="-14.2" spread="19.33"/>
                    <measurement group_id="O8" value="-16.4" spread="18.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.7" spread="23.03"/>
                    <measurement group_id="O2" value="-9.8" spread="18.35"/>
                    <measurement group_id="O3" value="-18.5" spread="22.70"/>
                    <measurement group_id="O4" value="-15.9" spread="14.77"/>
                    <measurement group_id="O5" value="-16.4" spread="24.02"/>
                    <measurement group_id="O6" value="-11.4" spread="20.57"/>
                    <measurement group_id="O7" value="-17.8" spread="23.49"/>
                    <measurement group_id="O8" value="-14.7" spread="12.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.4" spread="28.02"/>
                    <measurement group_id="O2" value="-9.2" spread="15.57"/>
                    <measurement group_id="O3" value="-14.7" spread="23.67"/>
                    <measurement group_id="O4" value="-17.7" spread="16.88"/>
                    <measurement group_id="O5" value="-22.8" spread="23.35"/>
                    <measurement group_id="O6" value="-9.5" spread="16.32"/>
                    <measurement group_id="O7" value="-15.0" spread="24.61"/>
                    <measurement group_id="O8" value="-14.2" spread="13.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.4" spread="27.91"/>
                    <measurement group_id="O2" value="-8.4" spread="18.57"/>
                    <measurement group_id="O3" value="-20.0" spread="28.15"/>
                    <measurement group_id="O4" value="-14.9" spread="14.69"/>
                    <measurement group_id="O5" value="-21.6" spread="23.42"/>
                    <measurement group_id="O6" value="-9.9" spread="20.54"/>
                    <measurement group_id="O7" value="-20.7" spread="29.18"/>
                    <measurement group_id="O8" value="-12.9" spread="14.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-21.0" spread="31.09"/>
                    <measurement group_id="O6" value="-11.4" spread="21.87"/>
                    <measurement group_id="O7" value="-21.8" spread="22.14"/>
                    <measurement group_id="O8" value="-13.3" spread="21.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-18.5" spread="28.19"/>
                    <measurement group_id="O6" value="-10.2" spread="22.65"/>
                    <measurement group_id="O7" value="-18.9" spread="31.30"/>
                    <measurement group_id="O8" value="-13.9" spread="18.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-19.4" spread="30.09"/>
                    <measurement group_id="O6" value="-14.1" spread="29.22"/>
                    <measurement group_id="O7" value="-16.0" spread="31.43"/>
                    <measurement group_id="O8" value="-14.1" spread="17.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-19.5" spread="25.19"/>
                    <measurement group_id="O6" value="-10.5" spread="28.04"/>
                    <measurement group_id="O7" value="-16.6" spread="27.97"/>
                    <measurement group_id="O8" value="-10.3" spread="17.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-22.6" spread="28.54"/>
                    <measurement group_id="O6" value="-15.1" spread="35.60"/>
                    <measurement group_id="O7" value="-18.2" spread="29.42"/>
                    <measurement group_id="O8" value="-8.3" spread="16.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-20.3" spread="29.20"/>
                    <measurement group_id="O6" value="-13.9" spread="34.19"/>
                    <measurement group_id="O7" value="-20.8" spread="30.17"/>
                    <measurement group_id="O8" value="-10.1" spread="20.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-21.5" spread="26.83"/>
                    <measurement group_id="O6" value="-13.8" spread="36.26"/>
                    <measurement group_id="O7" value="-20.8" spread="30.07"/>
                    <measurement group_id="O8" value="-8.8" spread="17.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-23.5" spread="26.93"/>
                    <measurement group_id="O6" value="-14.2" spread="33.99"/>
                    <measurement group_id="O7" value="-17.3" spread="28.80"/>
                    <measurement group_id="O8" value="-8.3" spread="17.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-21.3" spread="31.66"/>
                    <measurement group_id="O6" value="-8.2" spread="27.93"/>
                    <measurement group_id="O7" value="-16.6" spread="27.52"/>
                    <measurement group_id="O8" value="-7.3" spread="17.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-19.9" spread="27.82"/>
                    <measurement group_id="O6" value="-7.1" spread="24.97"/>
                    <measurement group_id="O7" value="-19.1" spread="31.38"/>
                    <measurement group_id="O8" value="-5.6" spread="17.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-21.3" spread="29.91"/>
                    <measurement group_id="O6" value="-6.5" spread="21.29"/>
                    <measurement group_id="O7" value="-17.7" spread="31.37"/>
                    <measurement group_id="O8" value="-5.5" spread="15.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-22.5" spread="26.09"/>
                    <measurement group_id="O6" value="-10.5" spread="26.79"/>
                    <measurement group_id="O7" value="-18.9" spread="33.97"/>
                    <measurement group_id="O8" value="-4.0" spread="14.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Participant's Global Assessment of Disease Activity Based on VAS Score at Each Visit Based on LOCF</title>
        <description>Participants were evaluated on their disease activity of RA, and entered the result on the score sheet, disease activity assessments reported by the participant, by placing a mark on a 100 mm horizontal VAS. The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity). Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant's Global Assessment of Disease Activity Based on VAS Score at Each Visit Based on LOCF</title>
          <description>Participants were evaluated on their disease activity of RA, and entered the result on the score sheet, disease activity assessments reported by the participant, by placing a mark on a 100 mm horizontal VAS. The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity). Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.2" spread="31.20"/>
                    <measurement group_id="O2" value="54.9" spread="32.83"/>
                    <measurement group_id="O3" value="55.6" spread="34.74"/>
                    <measurement group_id="O4" value="57.7" spread="20.12"/>
                    <measurement group_id="O5" value="57.2" spread="27.56"/>
                    <measurement group_id="O6" value="51.0" spread="32.93"/>
                    <measurement group_id="O7" value="52.3" spread="33.74"/>
                    <measurement group_id="O8" value="53.9" spread="18.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="10.52"/>
                    <measurement group_id="O2" value="-4.1" spread="13.20"/>
                    <measurement group_id="O3" value="-4.6" spread="20.66"/>
                    <measurement group_id="O4" value="-4.7" spread="14.21"/>
                    <measurement group_id="O5" value="-2.6" spread="10.59"/>
                    <measurement group_id="O6" value="-4.2" spread="14.70"/>
                    <measurement group_id="O7" value="-3.6" spread="21.18"/>
                    <measurement group_id="O8" value="-2.7" spread="14.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="16.76"/>
                    <measurement group_id="O2" value="-12.7" spread="25.46"/>
                    <measurement group_id="O3" value="-7.4" spread="24.36"/>
                    <measurement group_id="O4" value="-3.9" spread="14.72"/>
                    <measurement group_id="O5" value="-9.3" spread="17.76"/>
                    <measurement group_id="O6" value="-11.5" spread="25.73"/>
                    <measurement group_id="O7" value="-5.5" spread="24.34"/>
                    <measurement group_id="O8" value="-7.0" spread="13.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="19.27"/>
                    <measurement group_id="O2" value="-13.4" spread="29.22"/>
                    <measurement group_id="O3" value="-8.9" spread="24.79"/>
                    <measurement group_id="O4" value="-14.8" spread="16.50"/>
                    <measurement group_id="O5" value="-12.3" spread="19.83"/>
                    <measurement group_id="O6" value="-11.6" spread="32.31"/>
                    <measurement group_id="O7" value="-6.0" spread="23.28"/>
                    <measurement group_id="O8" value="-13.4" spread="15.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="25.53"/>
                    <measurement group_id="O2" value="-6.9" spread="23.69"/>
                    <measurement group_id="O3" value="-13.1" spread="22.86"/>
                    <measurement group_id="O4" value="-13.1" spread="20.03"/>
                    <measurement group_id="O5" value="-8.5" spread="24.24"/>
                    <measurement group_id="O6" value="-5.8" spread="24.73"/>
                    <measurement group_id="O7" value="-12.2" spread="23.48"/>
                    <measurement group_id="O8" value="-13.9" spread="18.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.0" spread="25.59"/>
                    <measurement group_id="O2" value="-7.4" spread="18.94"/>
                    <measurement group_id="O3" value="-14.1" spread="24.07"/>
                    <measurement group_id="O4" value="-13.5" spread="17.73"/>
                    <measurement group_id="O5" value="-16.2" spread="27.05"/>
                    <measurement group_id="O6" value="-9.5" spread="20.91"/>
                    <measurement group_id="O7" value="-13.6" spread="24.99"/>
                    <measurement group_id="O8" value="-13.0" spread="18.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" spread="27.33"/>
                    <measurement group_id="O2" value="-8.4" spread="14.28"/>
                    <measurement group_id="O3" value="-12.7" spread="26.93"/>
                    <measurement group_id="O4" value="-16.8" spread="20.74"/>
                    <measurement group_id="O5" value="-20.9" spread="24.16"/>
                    <measurement group_id="O6" value="-9.4" spread="15.21"/>
                    <measurement group_id="O7" value="-12.4" spread="28.00"/>
                    <measurement group_id="O8" value="-13.6" spread="19.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.9" spread="27.17"/>
                    <measurement group_id="O2" value="-8.8" spread="16.43"/>
                    <measurement group_id="O3" value="-16.3" spread="27.10"/>
                    <measurement group_id="O4" value="-12.3" spread="13.50"/>
                    <measurement group_id="O5" value="-20.0" spread="24.13"/>
                    <measurement group_id="O6" value="-10.8" spread="17.92"/>
                    <measurement group_id="O7" value="-16.2" spread="28.20"/>
                    <measurement group_id="O8" value="-11.3" spread="14.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-19.2" spread="27.12"/>
                    <measurement group_id="O6" value="-13.7" spread="22.84"/>
                    <measurement group_id="O7" value="-17.7" spread="21.66"/>
                    <measurement group_id="O8" value="-11.2" spread="25.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-17.4" spread="23.95"/>
                    <measurement group_id="O6" value="-10.5" spread="24.46"/>
                    <measurement group_id="O7" value="-14.2" spread="24.86"/>
                    <measurement group_id="O8" value="-10.3" spread="21.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-18.7" spread="27.02"/>
                    <measurement group_id="O6" value="-17.4" spread="31.23"/>
                    <measurement group_id="O7" value="-9.5" spread="25.94"/>
                    <measurement group_id="O8" value="-10.9" spread="21.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-17.7" spread="22.48"/>
                    <measurement group_id="O6" value="-13.3" spread="26.52"/>
                    <measurement group_id="O7" value="-14.5" spread="24.66"/>
                    <measurement group_id="O8" value="-7.7" spread="18.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-22.9" spread="27.86"/>
                    <measurement group_id="O6" value="-16.5" spread="32.23"/>
                    <measurement group_id="O7" value="-14.5" spread="25.67"/>
                    <measurement group_id="O8" value="-5.2" spread="17.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-22.9" spread="27.38"/>
                    <measurement group_id="O6" value="-17.2" spread="35.22"/>
                    <measurement group_id="O7" value="-16.5" spread="26.51"/>
                    <measurement group_id="O8" value="-5.3" spread="21.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-20.9" spread="24.80"/>
                    <measurement group_id="O6" value="-18.3" spread="35.75"/>
                    <measurement group_id="O7" value="-16.6" spread="25.83"/>
                    <measurement group_id="O8" value="-4.0" spread="19.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-23.5" spread="25.13"/>
                    <measurement group_id="O6" value="-16.6" spread="34.47"/>
                    <measurement group_id="O7" value="-13.2" spread="23.44"/>
                    <measurement group_id="O8" value="-3.5" spread="19.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-21.4" spread="29.91"/>
                    <measurement group_id="O6" value="-11.2" spread="27.25"/>
                    <measurement group_id="O7" value="-12.8" spread="23.57"/>
                    <measurement group_id="O8" value="-4.7" spread="20.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-20.5" spread="26.49"/>
                    <measurement group_id="O6" value="-9.2" spread="27.18"/>
                    <measurement group_id="O7" value="-14.1" spread="25.89"/>
                    <measurement group_id="O8" value="-2.3" spread="19.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-20.7" spread="28.39"/>
                    <measurement group_id="O6" value="-8.2" spread="22.01"/>
                    <measurement group_id="O7" value="-13.5" spread="24.90"/>
                    <measurement group_id="O8" value="-0.9" spread="17.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-21.9" spread="24.06"/>
                    <measurement group_id="O6" value="-13.5" spread="27.56"/>
                    <measurement group_id="O7" value="-14.2" spread="27.03"/>
                    <measurement group_id="O8" value="0.2" spread="16.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on VAS Score at Each Visit Based on LOCF</title>
        <description>The Physician's Global Assessment of Disease Activity was recorded using the 100 mm horizontal VAS. Physician rated participant's RA disease activity on a scale ranged from 0-100 mm, where 0 indicated no disease activity (no arthritis) and 100 represented maximum disease activity (maximum arthritis). Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on VAS Score at Each Visit Based on LOCF</title>
          <description>The Physician's Global Assessment of Disease Activity was recorded using the 100 mm horizontal VAS. Physician rated participant's RA disease activity on a scale ranged from 0-100 mm, where 0 indicated no disease activity (no arthritis) and 100 represented maximum disease activity (maximum arthritis). Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" spread="29.63"/>
                    <measurement group_id="O2" value="57.9" spread="22.02"/>
                    <measurement group_id="O3" value="62.4" spread="19.41"/>
                    <measurement group_id="O4" value="54.0" spread="27.28"/>
                    <measurement group_id="O5" value="60.8" spread="30.56"/>
                    <measurement group_id="O6" value="56.4" spread="22.41"/>
                    <measurement group_id="O7" value="60.5" spread="18.80"/>
                    <measurement group_id="O8" value="49.6" spread="27.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.8" spread="16.83"/>
                    <measurement group_id="O2" value="-13.6" spread="17.95"/>
                    <measurement group_id="O3" value="-13.3" spread="23.08"/>
                    <measurement group_id="O4" value="-8.1" spread="18.53"/>
                    <measurement group_id="O5" value="-15.6" spread="17.52"/>
                    <measurement group_id="O6" value="-16.8" spread="17.66"/>
                    <measurement group_id="O7" value="-13.9" spread="23.89"/>
                    <measurement group_id="O8" value="-6.6" spread="20.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.7" spread="13.62"/>
                    <measurement group_id="O2" value="-16.8" spread="19.68"/>
                    <measurement group_id="O3" value="-17.8" spread="27.46"/>
                    <measurement group_id="O4" value="-10.1" spread="16.68"/>
                    <measurement group_id="O5" value="-18.2" spread="12.60"/>
                    <measurement group_id="O6" value="-16.7" spread="16.88"/>
                    <measurement group_id="O7" value="-17.7" spread="28.58"/>
                    <measurement group_id="O8" value="-12.7" spread="17.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.8" spread="26.32"/>
                    <measurement group_id="O2" value="-17.6" spread="21.57"/>
                    <measurement group_id="O3" value="-19.6" spread="27.81"/>
                    <measurement group_id="O4" value="-13.8" spread="18.01"/>
                    <measurement group_id="O5" value="-17.7" spread="22.40"/>
                    <measurement group_id="O6" value="-17.7" spread="20.60"/>
                    <measurement group_id="O7" value="-20.3" spread="28.83"/>
                    <measurement group_id="O8" value="-14.6" spread="19.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.3" spread="26.50"/>
                    <measurement group_id="O2" value="-9.4" spread="21.99"/>
                    <measurement group_id="O3" value="-19.0" spread="30.18"/>
                    <measurement group_id="O4" value="-14.7" spread="21.15"/>
                    <measurement group_id="O5" value="-20.5" spread="24.71"/>
                    <measurement group_id="O6" value="-11.5" spread="20.62"/>
                    <measurement group_id="O7" value="-20.8" spread="30.65"/>
                    <measurement group_id="O8" value="-17.2" spread="22.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.4" spread="30.15"/>
                    <measurement group_id="O2" value="-19.7" spread="20.22"/>
                    <measurement group_id="O3" value="-23.4" spread="29.34"/>
                    <measurement group_id="O4" value="-14.5" spread="23.89"/>
                    <measurement group_id="O5" value="-23.6" spread="29.57"/>
                    <measurement group_id="O6" value="-23.1" spread="20.53"/>
                    <measurement group_id="O7" value="-24.5" spread="30.19"/>
                    <measurement group_id="O8" value="-16.7" spread="25.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.9" spread="25.67"/>
                    <measurement group_id="O2" value="-24.3" spread="22.97"/>
                    <measurement group_id="O3" value="-20.6" spread="27.81"/>
                    <measurement group_id="O4" value="-19.1" spread="20.38"/>
                    <measurement group_id="O5" value="-25.9" spread="25.94"/>
                    <measurement group_id="O6" value="-30.2" spread="20.74"/>
                    <measurement group_id="O7" value="-21.7" spread="28.61"/>
                    <measurement group_id="O8" value="-19.7" spread="19.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.7" spread="30.38"/>
                    <measurement group_id="O2" value="-18.3" spread="21.35"/>
                    <measurement group_id="O3" value="-17.6" spread="26.03"/>
                    <measurement group_id="O4" value="-10.0" spread="23.18"/>
                    <measurement group_id="O5" value="-34.8" spread="32.06"/>
                    <measurement group_id="O6" value="-22.6" spread="20.34"/>
                    <measurement group_id="O7" value="-18.5" spread="26.87"/>
                    <measurement group_id="O8" value="-8.9" spread="23.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-35.1" spread="36.51"/>
                    <measurement group_id="O6" value="-25.0" spread="24.91"/>
                    <measurement group_id="O7" value="-20.7" spread="29.71"/>
                    <measurement group_id="O8" value="-15.6" spread="42.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-35.2" spread="38.69"/>
                    <measurement group_id="O6" value="-17.2" spread="26.17"/>
                    <measurement group_id="O7" value="-16.3" spread="29.29"/>
                    <measurement group_id="O8" value="-7.5" spread="34.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-31.2" spread="34.51"/>
                    <measurement group_id="O6" value="-22.9" spread="26.79"/>
                    <measurement group_id="O7" value="-18.7" spread="31.17"/>
                    <measurement group_id="O8" value="-6.8" spread="33.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-30.4" spread="33.71"/>
                    <measurement group_id="O6" value="-22.4" spread="26.72"/>
                    <measurement group_id="O7" value="-22.7" spread="31.60"/>
                    <measurement group_id="O8" value="-2.9" spread="36.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-30.6" spread="29.64"/>
                    <measurement group_id="O6" value="-20.6" spread="22.65"/>
                    <measurement group_id="O7" value="-19.5" spread="29.54"/>
                    <measurement group_id="O8" value="0.4" spread="34.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-26.9" spread="28.12"/>
                    <measurement group_id="O6" value="-24.7" spread="26.27"/>
                    <measurement group_id="O7" value="-21.2" spread="30.95"/>
                    <measurement group_id="O8" value="3.7" spread="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-23.6" spread="26.84"/>
                    <measurement group_id="O6" value="-23.8" spread="30.00"/>
                    <measurement group_id="O7" value="-22.4" spread="32.85"/>
                    <measurement group_id="O8" value="4.0" spread="32.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-28.6" spread="33.01"/>
                    <measurement group_id="O6" value="-23.0" spread="28.85"/>
                    <measurement group_id="O7" value="-19.0" spread="32.29"/>
                    <measurement group_id="O8" value="8.2" spread="29.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-26.6" spread="34.81"/>
                    <measurement group_id="O6" value="-20.2" spread="26.75"/>
                    <measurement group_id="O7" value="-24.4" spread="33.78"/>
                    <measurement group_id="O8" value="6.0" spread="29.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-25.8" spread="32.03"/>
                    <measurement group_id="O6" value="-19.7" spread="30.66"/>
                    <measurement group_id="O7" value="-26.3" spread="36.36"/>
                    <measurement group_id="O8" value="8.6" spread="27.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-28.4" spread="32.79"/>
                    <measurement group_id="O6" value="-14.7" spread="28.22"/>
                    <measurement group_id="O7" value="-20.6" spread="31.61"/>
                    <measurement group_id="O8" value="6.8" spread="27.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-26.5" spread="32.75"/>
                    <measurement group_id="O6" value="-19.0" spread="31.12"/>
                    <measurement group_id="O7" value="-24.7" spread="36.95"/>
                    <measurement group_id="O8" value="8.5" spread="25.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Each Visit Based on LOCF</title>
        <description>Degree of disability was self-evaluated by participant using HAQ-DI.Assessment was made based on activities capable without any aids/devices.20-question instrument assessed degree of difficulty person had in accomplishing tasks in 8 functional areas(dressing,arising,eating,walking,hygiene,reaching,gripping,and activities of daily living).Responses in each functional area were scored from 0(indicated no difficulty)to 3(indicated inability to perform task in that area).Overall score computed as: sum of domain scores and divided by number of domains answered.Total possible score range:0-3 where 0=least difficulty and 3=extreme difficulty.Data for Core Treatment Phase from Week 0-10 is reported according to participant re-randomization in 4 arms at Week 12.Data reported for Extension Phase from Baseline to Week 24,is same data for Core Treatment Phase,but excluding participants who received at least 1 dose of drug and had at least 1 postdose primary efficacy measurement after Week 24-72.</description>
        <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Each Visit Based on LOCF</title>
          <description>Degree of disability was self-evaluated by participant using HAQ-DI.Assessment was made based on activities capable without any aids/devices.20-question instrument assessed degree of difficulty person had in accomplishing tasks in 8 functional areas(dressing,arising,eating,walking,hygiene,reaching,gripping,and activities of daily living).Responses in each functional area were scored from 0(indicated no difficulty)to 3(indicated inability to perform task in that area).Overall score computed as: sum of domain scores and divided by number of domains answered.Total possible score range:0-3 where 0=least difficulty and 3=extreme difficulty.Data for Core Treatment Phase from Week 0-10 is reported according to participant re-randomization in 4 arms at Week 12.Data reported for Extension Phase from Baseline to Week 24,is same data for Core Treatment Phase,but excluding participants who received at least 1 dose of drug and had at least 1 postdose primary efficacy measurement after Week 24-72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.816"/>
                    <measurement group_id="O2" value="1.04" spread="0.770"/>
                    <measurement group_id="O3" value="0.88" spread="0.744"/>
                    <measurement group_id="O4" value="1.08" spread="0.673"/>
                    <measurement group_id="O5" value="0.85" spread="0.702"/>
                    <measurement group_id="O6" value="1.20" spread="0.789"/>
                    <measurement group_id="O7" value="0.76" spread="0.605"/>
                    <measurement group_id="O8" value="0.94" spread="0.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.163"/>
                    <measurement group_id="O2" value="-0.03" spread="0.399"/>
                    <measurement group_id="O3" value="-0.08" spread="0.297"/>
                    <measurement group_id="O4" value="0.01" spread="0.258"/>
                    <measurement group_id="O5" value="0.07" spread="0.174"/>
                    <measurement group_id="O6" value="-0.08" spread="0.423"/>
                    <measurement group_id="O7" value="-0.04" spread="0.262"/>
                    <measurement group_id="O8" value="0.00" spread="0.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.197"/>
                    <measurement group_id="O2" value="-0.25" spread="0.460"/>
                    <measurement group_id="O3" value="-0.10" spread="0.371"/>
                    <measurement group_id="O4" value="-0.03" spread="0.316"/>
                    <measurement group_id="O5" value="0.02" spread="0.203"/>
                    <measurement group_id="O6" value="-0.30" spread="0.485"/>
                    <measurement group_id="O7" value="-0.05" spread="0.333"/>
                    <measurement group_id="O8" value="-0.05" spread="0.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.181"/>
                    <measurement group_id="O2" value="-0.38" spread="0.595"/>
                    <measurement group_id="O3" value="-0.10" spread="0.344"/>
                    <measurement group_id="O4" value="-0.05" spread="0.404"/>
                    <measurement group_id="O5" value="-0.07" spread="0.174"/>
                    <measurement group_id="O6" value="-0.47" spread="0.647"/>
                    <measurement group_id="O7" value="-0.09" spread="0.355"/>
                    <measurement group_id="O8" value="-0.10" spread="0.428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.358"/>
                    <measurement group_id="O2" value="-0.25" spread="0.357"/>
                    <measurement group_id="O3" value="-0.06" spread="0.459"/>
                    <measurement group_id="O4" value="-0.02" spread="0.497"/>
                    <measurement group_id="O5" value="0.10" spread="0.369"/>
                    <measurement group_id="O6" value="-0.34" spread="0.340"/>
                    <measurement group_id="O7" value="-0.07" spread="0.478"/>
                    <measurement group_id="O8" value="-0.04" spread="0.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.376"/>
                    <measurement group_id="O2" value="-0.11" spread="0.395"/>
                    <measurement group_id="O3" value="-0.11" spread="0.495"/>
                    <measurement group_id="O4" value="-0.04" spread="0.421"/>
                    <measurement group_id="O5" value="0.02" spread="0.405"/>
                    <measurement group_id="O6" value="-0.22" spread="0.354"/>
                    <measurement group_id="O7" value="-0.13" spread="0.510"/>
                    <measurement group_id="O8" value="-0.04" spread="0.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.400"/>
                    <measurement group_id="O2" value="-0.21" spread="0.341"/>
                    <measurement group_id="O3" value="-0.15" spread="0.619"/>
                    <measurement group_id="O4" value="-0.02" spread="0.579"/>
                    <measurement group_id="O5" value="-0.07" spread="0.426"/>
                    <measurement group_id="O6" value="-0.30" spread="0.341"/>
                    <measurement group_id="O7" value="-0.19" spread="0.624"/>
                    <measurement group_id="O8" value="0.04" spread="0.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.483"/>
                    <measurement group_id="O2" value="-0.23" spread="0.395"/>
                    <measurement group_id="O3" value="-0.23" spread="0.574"/>
                    <measurement group_id="O4" value="0.02" spread="0.464"/>
                    <measurement group_id="O5" value="-0.07" spread="0.517"/>
                    <measurement group_id="O6" value="-0.33" spread="0.388"/>
                    <measurement group_id="O7" value="-0.28" spread="0.569"/>
                    <measurement group_id="O8" value="0.04" spread="0.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.10" spread="0.521"/>
                    <measurement group_id="O6" value="-0.31" spread="0.401"/>
                    <measurement group_id="O7" value="-0.25" spread="0.448"/>
                    <measurement group_id="O8" value="0.23" spread="0.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.09" spread="0.596"/>
                    <measurement group_id="O6" value="-0.26" spread="0.469"/>
                    <measurement group_id="O7" value="-0.13" spread="0.518"/>
                    <measurement group_id="O8" value="0.06" spread="0.461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.13" spread="0.545"/>
                    <measurement group_id="O6" value="-0.23" spread="0.467"/>
                    <measurement group_id="O7" value="-0.18" spread="0.450"/>
                    <measurement group_id="O8" value="0.19" spread="0.409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.04" spread="0.620"/>
                    <measurement group_id="O6" value="-0.26" spread="0.495"/>
                    <measurement group_id="O7" value="-0.16" spread="0.458"/>
                    <measurement group_id="O8" value="0.18" spread="0.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.10" spread="0.557"/>
                    <measurement group_id="O6" value="-0.24" spread="0.514"/>
                    <measurement group_id="O7" value="-0.18" spread="0.441"/>
                    <measurement group_id="O8" value="0.26" spread="0.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.13" spread="0.534"/>
                    <measurement group_id="O6" value="-0.31" spread="0.566"/>
                    <measurement group_id="O7" value="-0.18" spread="0.464"/>
                    <measurement group_id="O8" value="0.23" spread="0.432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.14" spread="0.588"/>
                    <measurement group_id="O6" value="-0.25" spread="0.565"/>
                    <measurement group_id="O7" value="-0.21" spread="0.443"/>
                    <measurement group_id="O8" value="0.24" spread="0.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.14" spread="0.629"/>
                    <measurement group_id="O6" value="-0.25" spread="0.565"/>
                    <measurement group_id="O7" value="-0.19" spread="0.429"/>
                    <measurement group_id="O8" value="0.28" spread="0.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.13" spread="0.664"/>
                    <measurement group_id="O6" value="-0.20" spread="0.522"/>
                    <measurement group_id="O7" value="-0.12" spread="0.452"/>
                    <measurement group_id="O8" value="0.24" spread="0.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.14" spread="0.682"/>
                    <measurement group_id="O6" value="-0.18" spread="0.534"/>
                    <measurement group_id="O7" value="-0.16" spread="0.496"/>
                    <measurement group_id="O8" value="0.28" spread="0.471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.13" spread="0.672"/>
                    <measurement group_id="O6" value="-0.22" spread="0.542"/>
                    <measurement group_id="O7" value="-0.17" spread="0.480"/>
                    <measurement group_id="O8" value="0.25" spread="0.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.17" spread="0.632"/>
                    <measurement group_id="O6" value="-0.20" spread="0.540"/>
                    <measurement group_id="O7" value="-0.15" spread="0.575"/>
                    <measurement group_id="O8" value="0.24" spread="0.473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-reactive Protein (CRP) Values at Each Visit Based on LOCF</title>
        <description>CRP of each participants was measured as a part of blood biochemical tests. A normal CRP value is less than (&lt;) 10 milligram per deciliter (mg/dL). A test result showing a CRP level greater than 10 mg/dL is a sign of chronic disease. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-reactive Protein (CRP) Values at Each Visit Based on LOCF</title>
          <description>CRP of each participants was measured as a part of blood biochemical tests. A normal CRP value is less than (&lt;) 10 milligram per deciliter (mg/dL). A test result showing a CRP level greater than 10 mg/dL is a sign of chronic disease. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="1.299"/>
                    <measurement group_id="O2" value="2.50" spread="4.012"/>
                    <measurement group_id="O3" value="3.09" spread="3.186"/>
                    <measurement group_id="O4" value="1.68" spread="2.504"/>
                    <measurement group_id="O5" value="0.94" spread="1.097"/>
                    <measurement group_id="O6" value="1.83" spread="2.893"/>
                    <measurement group_id="O7" value="3.10" spread="3.316"/>
                    <measurement group_id="O8" value="0.81" spread="0.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.795"/>
                    <measurement group_id="O2" value="0.02" spread="1.701"/>
                    <measurement group_id="O3" value="-0.39" spread="1.438"/>
                    <measurement group_id="O4" value="-0.13" spread="0.870"/>
                    <measurement group_id="O5" value="0.46" spread="0.855"/>
                    <measurement group_id="O6" value="0.23" spread="1.782"/>
                    <measurement group_id="O7" value="-0.45" spread="1.473"/>
                    <measurement group_id="O8" value="-0.11" spread="0.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.507"/>
                    <measurement group_id="O2" value="-0.63" spread="2.308"/>
                    <measurement group_id="O3" value="-0.25" spread="0.938"/>
                    <measurement group_id="O4" value="0.73" spread="3.043"/>
                    <measurement group_id="O5" value="0.23" spread="0.525"/>
                    <measurement group_id="O6" value="-0.01" spread="0.636"/>
                    <measurement group_id="O7" value="-0.30" spread="0.957"/>
                    <measurement group_id="O8" value="-0.02" spread="0.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.579"/>
                    <measurement group_id="O2" value="-0.33" spread="2.229"/>
                    <measurement group_id="O3" value="-0.09" spread="1.277"/>
                    <measurement group_id="O4" value="0.43" spread="1.644"/>
                    <measurement group_id="O5" value="0.05" spread="0.389"/>
                    <measurement group_id="O6" value="0.30" spread="0.518"/>
                    <measurement group_id="O7" value="-0.20" spread="1.262"/>
                    <measurement group_id="O8" value="0.07" spread="0.680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.978"/>
                    <measurement group_id="O2" value="-0.44" spread="1.643"/>
                    <measurement group_id="O3" value="0.07" spread="2.524"/>
                    <measurement group_id="O4" value="0.40" spread="1.618"/>
                    <measurement group_id="O5" value="0.32" spread="0.814"/>
                    <measurement group_id="O6" value="-0.18" spread="0.810"/>
                    <measurement group_id="O7" value="0.02" spread="2.618"/>
                    <measurement group_id="O8" value="0.33" spread="1.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="1.090"/>
                    <measurement group_id="O2" value="-0.42" spread="1.755"/>
                    <measurement group_id="O3" value="0.08" spread="1.943"/>
                    <measurement group_id="O4" value="0.63" spread="2.343"/>
                    <measurement group_id="O5" value="0.22" spread="0.965"/>
                    <measurement group_id="O6" value="-0.10" spread="0.835"/>
                    <measurement group_id="O7" value="-0.09" spread="1.909"/>
                    <measurement group_id="O8" value="0.28" spread="0.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="1.278"/>
                    <measurement group_id="O2" value="-0.41" spread="1.792"/>
                    <measurement group_id="O3" value="0.49" spread="2.713"/>
                    <measurement group_id="O4" value="0.56" spread="2.257"/>
                    <measurement group_id="O5" value="0.36" spread="1.180"/>
                    <measurement group_id="O6" value="-0.10" spread="0.849"/>
                    <measurement group_id="O7" value="0.35" spread="2.771"/>
                    <measurement group_id="O8" value="0.37" spread="0.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="1.144"/>
                    <measurement group_id="O2" value="-0.31" spread="1.692"/>
                    <measurement group_id="O3" value="-0.49" spread="2.893"/>
                    <measurement group_id="O4" value="0.47" spread="2.047"/>
                    <measurement group_id="O5" value="0.38" spread="1.004"/>
                    <measurement group_id="O6" value="0.15" spread="0.652"/>
                    <measurement group_id="O7" value="-0.71" spread="2.892"/>
                    <measurement group_id="O8" value="0.65" spread="1.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.42" spread="1.023"/>
                    <measurement group_id="O6" value="0.02" spread="1.301"/>
                    <measurement group_id="O7" value="-0.65" spread="3.002"/>
                    <measurement group_id="O8" value="0.75" spread="1.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.48" spread="1.250"/>
                    <measurement group_id="O6" value="0.09" spread="1.818"/>
                    <measurement group_id="O7" value="-1.12" spread="2.881"/>
                    <measurement group_id="O8" value="0.69" spread="1.610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.81" spread="1.834"/>
                    <measurement group_id="O6" value="0.10" spread="1.625"/>
                    <measurement group_id="O7" value="-1.16" spread="2.638"/>
                    <measurement group_id="O8" value="0.67" spread="1.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.75" spread="1.825"/>
                    <measurement group_id="O6" value="0.25" spread="1.490"/>
                    <measurement group_id="O7" value="-0.42" spread="1.840"/>
                    <measurement group_id="O8" value="1.01" spread="2.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="1.08" spread="1.857"/>
                    <measurement group_id="O6" value="0.38" spread="1.459"/>
                    <measurement group_id="O7" value="-0.50" spread="3.730"/>
                    <measurement group_id="O8" value="0.86" spread="1.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.99" spread="1.783"/>
                    <measurement group_id="O6" value="0.21" spread="1.653"/>
                    <measurement group_id="O7" value="-1.04" spread="2.757"/>
                    <measurement group_id="O8" value="0.98" spread="1.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.83" spread="1.801"/>
                    <measurement group_id="O6" value="0.25" spread="1.642"/>
                    <measurement group_id="O7" value="-1.16" spread="3.002"/>
                    <measurement group_id="O8" value="0.72" spread="1.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.90" spread="1.859"/>
                    <measurement group_id="O6" value="0.63" spread="1.521"/>
                    <measurement group_id="O7" value="-1.04" spread="3.060"/>
                    <measurement group_id="O8" value="0.67" spread="1.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.80" spread="1.828"/>
                    <measurement group_id="O6" value="0.58" spread="1.405"/>
                    <measurement group_id="O7" value="-1.04" spread="3.168"/>
                    <measurement group_id="O8" value="0.69" spread="1.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.76" spread="1.803"/>
                    <measurement group_id="O6" value="0.47" spread="1.465"/>
                    <measurement group_id="O7" value="-0.87" spread="2.213"/>
                    <measurement group_id="O8" value="0.77" spread="1.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="1.10" spread="1.914"/>
                    <measurement group_id="O6" value="0.40" spread="1.641"/>
                    <measurement group_id="O7" value="-1.10" spread="2.565"/>
                    <measurement group_id="O8" value="0.67" spread="1.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.83" spread="1.791"/>
                    <measurement group_id="O6" value="0.29" spread="1.592"/>
                    <measurement group_id="O7" value="-0.94" spread="3.036"/>
                    <measurement group_id="O8" value="0.97" spread="1.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Erythrocyte Sedimentation Rate (ESR) Values at Each Visit Based on LOCF</title>
        <description>ESR were a type of blood test. An ESR was used to monitor the arthritis condition. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Erythrocyte Sedimentation Rate (ESR) Values at Each Visit Based on LOCF</title>
          <description>ESR were a type of blood test. An ESR was used to monitor the arthritis condition. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
          <units>millimeter per hour (mm/hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" spread="19.55"/>
                    <measurement group_id="O2" value="44.4" spread="25.70"/>
                    <measurement group_id="O3" value="51.8" spread="34.26"/>
                    <measurement group_id="O4" value="35.3" spread="18.44"/>
                    <measurement group_id="O5" value="33.9" spread="19.56"/>
                    <measurement group_id="O6" value="41.2" spread="25.81"/>
                    <measurement group_id="O7" value="49.9" spread="34.91"/>
                    <measurement group_id="O8" value="32.3" spread="18.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="14.36"/>
                    <measurement group_id="O2" value="0.2" spread="12.43"/>
                    <measurement group_id="O3" value="1.5" spread="11.63"/>
                    <measurement group_id="O4" value="1.5" spread="10.28"/>
                    <measurement group_id="O5" value="8.6" spread="15.37"/>
                    <measurement group_id="O6" value="-1.2" spread="13.39"/>
                    <measurement group_id="O7" value="-0.8" spread="8.28"/>
                    <measurement group_id="O8" value="-1.9" spread="6.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="14.66"/>
                    <measurement group_id="O2" value="2.1" spread="18.56"/>
                    <measurement group_id="O3" value="-0.3" spread="11.56"/>
                    <measurement group_id="O4" value="1.4" spread="15.41"/>
                    <measurement group_id="O5" value="9.5" spread="15.59"/>
                    <measurement group_id="O6" value="1.5" spread="16.66"/>
                    <measurement group_id="O7" value="-0.9" spread="11.77"/>
                    <measurement group_id="O8" value="-4.0" spread="9.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="9.53"/>
                    <measurement group_id="O2" value="5.4" spread="15.78"/>
                    <measurement group_id="O3" value="-0.5" spread="17.72"/>
                    <measurement group_id="O4" value="3.9" spread="21.68"/>
                    <measurement group_id="O5" value="4.6" spread="10.21"/>
                    <measurement group_id="O6" value="3.5" spread="14.36"/>
                    <measurement group_id="O7" value="-2.3" spread="17.05"/>
                    <measurement group_id="O8" value="-2.6" spread="16.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="10.14"/>
                    <measurement group_id="O2" value="5.1" spread="23.65"/>
                    <measurement group_id="O3" value="-1.5" spread="22.06"/>
                    <measurement group_id="O4" value="6.8" spread="19.60"/>
                    <measurement group_id="O5" value="2.1" spread="10.80"/>
                    <measurement group_id="O6" value="4.7" spread="21.64"/>
                    <measurement group_id="O7" value="-3.8" spread="21.06"/>
                    <measurement group_id="O8" value="4.5" spread="20.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="10.64"/>
                    <measurement group_id="O2" value="-3.4" spread="14.11"/>
                    <measurement group_id="O3" value="-3.0" spread="23.33"/>
                    <measurement group_id="O4" value="3.0" spread="23.46"/>
                    <measurement group_id="O5" value="5.8" spread="10.90"/>
                    <measurement group_id="O6" value="-3.4" spread="15.64"/>
                    <measurement group_id="O7" value="-3.5" spread="24.22"/>
                    <measurement group_id="O8" value="0.8" spread="23.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="12.72"/>
                    <measurement group_id="O2" value="-0.4" spread="11.04"/>
                    <measurement group_id="O3" value="1.2" spread="31.07"/>
                    <measurement group_id="O4" value="6.9" spread="18.59"/>
                    <measurement group_id="O5" value="2.8" spread="13.45"/>
                    <measurement group_id="O6" value="0.6" spread="11.96"/>
                    <measurement group_id="O7" value="-0.8" spread="31.33"/>
                    <measurement group_id="O8" value="2.7" spread="16.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="17.51"/>
                    <measurement group_id="O2" value="-2.7" spread="14.74"/>
                    <measurement group_id="O3" value="-0.1" spread="33.28"/>
                    <measurement group_id="O4" value="9.3" spread="19.00"/>
                    <measurement group_id="O5" value="9.6" spread="18.32"/>
                    <measurement group_id="O6" value="-2.4" spread="16.48"/>
                    <measurement group_id="O7" value="-2.3" spread="33.60"/>
                    <measurement group_id="O8" value="4.5" spread="15.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="6.5" spread="18.39"/>
                    <measurement group_id="O6" value="-6.1" spread="13.12"/>
                    <measurement group_id="O7" value="-5.2" spread="35.53"/>
                    <measurement group_id="O8" value="2.3" spread="21.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="10.1" spread="19.73"/>
                    <measurement group_id="O6" value="-2.5" spread="19.24"/>
                    <measurement group_id="O7" value="-7.4" spread="39.76"/>
                    <measurement group_id="O8" value="-0.8" spread="23.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="10.6" spread="19.70"/>
                    <measurement group_id="O6" value="-1.4" spread="20.41"/>
                    <measurement group_id="O7" value="-4.1" spread="30.55"/>
                    <measurement group_id="O8" value="-0.3" spread="25.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="12.2" spread="18.88"/>
                    <measurement group_id="O6" value="-3.8" spread="16.78"/>
                    <measurement group_id="O7" value="-3.4" spread="19.89"/>
                    <measurement group_id="O8" value="3.0" spread="31.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="12.2" spread="18.67"/>
                    <measurement group_id="O6" value="0.8" spread="17.87"/>
                    <measurement group_id="O7" value="-4.8" spread="21.23"/>
                    <measurement group_id="O8" value="8.1" spread="26.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="11.8" spread="18.90"/>
                    <measurement group_id="O6" value="-2.5" spread="18.18"/>
                    <measurement group_id="O7" value="-6.0" spread="25.17"/>
                    <measurement group_id="O8" value="5.7" spread="32.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="16.1" spread="17.46"/>
                    <measurement group_id="O6" value="-1.3" spread="18.77"/>
                    <measurement group_id="O7" value="-5.6" spread="26.41"/>
                    <measurement group_id="O8" value="0.9" spread="22.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="14.8" spread="20.93"/>
                    <measurement group_id="O6" value="1.4" spread="18.92"/>
                    <measurement group_id="O7" value="-6.3" spread="28.79"/>
                    <measurement group_id="O8" value="1.2" spread="26.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="15.2" spread="18.43"/>
                    <measurement group_id="O6" value="3.5" spread="19.91"/>
                    <measurement group_id="O7" value="-5.7" spread="28.67"/>
                    <measurement group_id="O8" value="3.7" spread="25.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="15.3" spread="17.84"/>
                    <measurement group_id="O6" value="1.0" spread="17.38"/>
                    <measurement group_id="O7" value="-3.5" spread="21.04"/>
                    <measurement group_id="O8" value="3.0" spread="26.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="16.5" spread="17.88"/>
                    <measurement group_id="O6" value="1.6" spread="20.10"/>
                    <measurement group_id="O7" value="-4.6" spread="23.94"/>
                    <measurement group_id="O8" value="2.8" spread="25.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="16.5" spread="18.00"/>
                    <measurement group_id="O6" value="3.1" spread="20.22"/>
                    <measurement group_id="O7" value="-4.4" spread="26.88"/>
                    <measurement group_id="O8" value="7.1" spread="28.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score 28 (DAS28)-ESR Values at Each Visit Based on LOCF</title>
        <description>The DAS28 index was a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, participant global assessment of disease activity score, and ESR value. Total score ranged between 0-10. A DAS28-ESR score of 5.1 or above=high disease activity, a value greater than (&gt;) 3.2 and less than or equal to (&lt;=) 5.1=moderate disease activity and value &lt;=3.2=low disease activity, value &lt;2.6=disease remission. A positive change in score indicates worsening, and a negative change indicates improvement. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score 28 (DAS28)-ESR Values at Each Visit Based on LOCF</title>
          <description>The DAS28 index was a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, participant global assessment of disease activity score, and ESR value. Total score ranged between 0-10. A DAS28-ESR score of 5.1 or above=high disease activity, a value greater than (&gt;) 3.2 and less than or equal to (&lt;=) 5.1=moderate disease activity and value &lt;=3.2=low disease activity, value &lt;2.6=disease remission. A positive change in score indicates worsening, and a negative change indicates improvement. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.479" spread="1.2520"/>
                    <measurement group_id="O2" value="5.870" spread="1.3037"/>
                    <measurement group_id="O3" value="5.951" spread="1.1584"/>
                    <measurement group_id="O4" value="5.971" spread="0.9561"/>
                    <measurement group_id="O5" value="5.460" spread="0.9793"/>
                    <measurement group_id="O6" value="5.696" spread="1.3749"/>
                    <measurement group_id="O7" value="5.849" spread="1.1389"/>
                    <measurement group_id="O8" value="5.623" spread="0.5133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.212" spread="0.5989"/>
                    <measurement group_id="O2" value="-0.340" spread="0.5440"/>
                    <measurement group_id="O3" value="-0.401" spread="0.7715"/>
                    <measurement group_id="O4" value="-0.658" spread="0.4838"/>
                    <measurement group_id="O5" value="-0.262" spread="0.6308"/>
                    <measurement group_id="O6" value="-0.363" spread="0.6115"/>
                    <measurement group_id="O7" value="-0.426" spread="0.7970"/>
                    <measurement group_id="O8" value="-0.593" spread="0.5036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.546" spread="1.1731"/>
                    <measurement group_id="O2" value="-0.674" spread="1.0013"/>
                    <measurement group_id="O3" value="-0.489" spread="1.0301"/>
                    <measurement group_id="O4" value="-0.870" spread="0.7421"/>
                    <measurement group_id="O5" value="-0.582" spread="1.2502"/>
                    <measurement group_id="O6" value="-0.697" spread="1.0573"/>
                    <measurement group_id="O7" value="-0.446" spread="1.0589"/>
                    <measurement group_id="O8" value="-0.971" spread="0.7646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.719" spread="0.9115"/>
                    <measurement group_id="O2" value="-0.797" spread="1.7366"/>
                    <measurement group_id="O3" value="-0.452" spread="1.0405"/>
                    <measurement group_id="O4" value="-1.098" spread="0.6243"/>
                    <measurement group_id="O5" value="-0.739" spread="0.9760"/>
                    <measurement group_id="O6" value="-0.928" spread="1.9411"/>
                    <measurement group_id="O7" value="-0.390" spread="1.0558"/>
                    <measurement group_id="O8" value="-1.199" spread="0.6263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.633" spread="1.1583"/>
                    <measurement group_id="O2" value="-0.532" spread="1.4324"/>
                    <measurement group_id="O3" value="-0.710" spread="1.2693"/>
                    <measurement group_id="O4" value="-1.012" spread="0.8396"/>
                    <measurement group_id="O5" value="-0.749" spread="1.1879"/>
                    <measurement group_id="O6" value="-0.654" spread="1.5342"/>
                    <measurement group_id="O7" value="-0.727" spread="1.3193"/>
                    <measurement group_id="O8" value="-1.121" spread="0.8512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.915" spread="1.3442"/>
                    <measurement group_id="O2" value="-1.005" spread="0.9633"/>
                    <measurement group_id="O3" value="-0.686" spread="1.2377"/>
                    <measurement group_id="O4" value="-1.431" spread="0.9735"/>
                    <measurement group_id="O5" value="-0.910" spread="1.4311"/>
                    <measurement group_id="O6" value="-1.148" spread="1.0416"/>
                    <measurement group_id="O7" value="-0.664" spread="1.2855"/>
                    <measurement group_id="O8" value="-1.475" spread="0.9937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.052" spread="1.2322"/>
                    <measurement group_id="O2" value="-0.983" spread="1.0665"/>
                    <measurement group_id="O3" value="-0.593" spread="1.4253"/>
                    <measurement group_id="O4" value="-1.459" spread="1.1873"/>
                    <measurement group_id="O5" value="-1.119" spread="1.3126"/>
                    <measurement group_id="O6" value="-1.114" spread="1.1754"/>
                    <measurement group_id="O7" value="-0.622" spread="1.4794"/>
                    <measurement group_id="O8" value="-1.316" spread="1.0018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.144" spread="1.3770"/>
                    <measurement group_id="O2" value="-0.880" spread="1.5753"/>
                    <measurement group_id="O3" value="-0.621" spread="1.4654"/>
                    <measurement group_id="O4" value="-1.237" spread="1.2485"/>
                    <measurement group_id="O5" value="-1.226" spread="1.4651"/>
                    <measurement group_id="O6" value="-0.996" spread="1.7744"/>
                    <measurement group_id="O7" value="-0.651" spread="1.5206"/>
                    <measurement group_id="O8" value="-1.250" spread="1.3487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-1.021" spread="1.5467"/>
                    <measurement group_id="O6" value="-1.400" spread="1.8959"/>
                    <measurement group_id="O7" value="-0.717" spread="1.5407"/>
                    <measurement group_id="O8" value="-1.265" spread="1.5622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.755" spread="1.5599"/>
                    <measurement group_id="O6" value="-1.015" spread="1.7114"/>
                    <measurement group_id="O7" value="-0.973" spread="2.0715"/>
                    <measurement group_id="O8" value="-1.283" spread="1.5960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-1.009" spread="1.6211"/>
                    <measurement group_id="O6" value="-1.136" spread="1.9269"/>
                    <measurement group_id="O7" value="-0.733" spread="1.6623"/>
                    <measurement group_id="O8" value="-1.210" spread="1.7566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.790" spread="1.5655"/>
                    <measurement group_id="O6" value="-1.167" spread="1.8142"/>
                    <measurement group_id="O7" value="-0.954" spread="1.7462"/>
                    <measurement group_id="O8" value="-0.976" spread="1.6523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.900" spread="1.6899"/>
                    <measurement group_id="O6" value="-1.156" spread="2.0018"/>
                    <measurement group_id="O7" value="-0.895" spread="1.7231"/>
                    <measurement group_id="O8" value="-0.736" spread="1.5585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.849" spread="1.5612"/>
                    <measurement group_id="O6" value="-1.316" spread="2.1913"/>
                    <measurement group_id="O7" value="-0.881" spread="1.7674"/>
                    <measurement group_id="O8" value="-0.697" spread="1.4635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.552" spread="1.3993"/>
                    <measurement group_id="O6" value="-1.283" spread="2.3802"/>
                    <measurement group_id="O7" value="-1.026" spread="1.8598"/>
                    <measurement group_id="O8" value="-1.146" spread="1.5067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.779" spread="1.5890"/>
                    <measurement group_id="O6" value="-1.262" spread="2.2876"/>
                    <measurement group_id="O7" value="-0.889" spread="1.8339"/>
                    <measurement group_id="O8" value="-0.967" spread="1.5410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.634" spread="1.4797"/>
                    <measurement group_id="O6" value="-0.804" spread="1.4963"/>
                    <measurement group_id="O7" value="-1.119" spread="2.0381"/>
                    <measurement group_id="O8" value="-0.991" spread="1.5604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.544" spread="1.4247"/>
                    <measurement group_id="O6" value="-0.683" spread="1.4337"/>
                    <measurement group_id="O7" value="-1.182" spread="2.0758"/>
                    <measurement group_id="O8" value="-0.925" spread="1.6162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.653" spread="1.4101"/>
                    <measurement group_id="O6" value="-0.854" spread="1.6351"/>
                    <measurement group_id="O7" value="-0.908" spread="2.1318"/>
                    <measurement group_id="O8" value="-0.830" spread="1.5182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.654" spread="1.4252"/>
                    <measurement group_id="O6" value="-1.076" spread="1.8640"/>
                    <measurement group_id="O7" value="-1.169" spread="2.1891"/>
                    <measurement group_id="O8" value="-0.684" spread="1.4746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28-CRP Values at Each Visit Based on LOCF</title>
        <description>The DAS28 index was a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, participant global assessment of disease activity score, and CRP value. Total score ranged between 0-10. A DAS28-CRP score of 4.1 or above=high disease activity, a value &gt;2.7 and &lt;=4.1=moderate disease activity and a value &lt;=2.7=low disease activity, value &lt;2.3=disease remission. A positive change in score indicates worsening, and a negative change indicates improvement. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-CRP Values at Each Visit Based on LOCF</title>
          <description>The DAS28 index was a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, participant global assessment of disease activity score, and CRP value. Total score ranged between 0-10. A DAS28-CRP score of 4.1 or above=high disease activity, a value &gt;2.7 and &lt;=4.1=moderate disease activity and a value &lt;=2.7=low disease activity, value &lt;2.3=disease remission. A positive change in score indicates worsening, and a negative change indicates improvement. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.842" spread="1.2628"/>
                    <measurement group_id="O2" value="5.194" spread="1.2869"/>
                    <measurement group_id="O3" value="5.305" spread="1.1055"/>
                    <measurement group_id="O4" value="5.318" spread="1.0756"/>
                    <measurement group_id="O5" value="4.780" spread="0.9932"/>
                    <measurement group_id="O6" value="5.033" spread="1.3186"/>
                    <measurement group_id="O7" value="5.218" spread="1.0996"/>
                    <measurement group_id="O8" value="4.909" spread="0.5330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.277" spread="0.5794"/>
                    <measurement group_id="O2" value="-0.313" spread="0.4086"/>
                    <measurement group_id="O3" value="-0.459" spread="0.7658"/>
                    <measurement group_id="O4" value="-0.691" spread="0.5431"/>
                    <measurement group_id="O5" value="-0.353" spread="0.5823"/>
                    <measurement group_id="O6" value="-0.314" spread="0.4634"/>
                    <measurement group_id="O7" value="-0.475" spread="0.7948"/>
                    <measurement group_id="O8" value="-0.596" spread="0.5478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.672" spread="1.0587"/>
                    <measurement group_id="O2" value="-0.653" spread="0.7404"/>
                    <measurement group_id="O3" value="-0.550" spread="1.0307"/>
                    <measurement group_id="O4" value="-0.808" spread="0.6209"/>
                    <measurement group_id="O5" value="-0.719" spread="1.1249"/>
                    <measurement group_id="O6" value="-0.607" spread="0.7575"/>
                    <measurement group_id="O7" value="-0.510" spread="1.0611"/>
                    <measurement group_id="O8" value="-0.881" spread="0.6595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.790" spread="0.8574"/>
                    <measurement group_id="O2" value="-0.806" spread="1.4652"/>
                    <measurement group_id="O3" value="-0.448" spread="1.0170"/>
                    <measurement group_id="O4" value="-1.108" spread="0.5967"/>
                    <measurement group_id="O5" value="-0.802" spread="0.9214"/>
                    <measurement group_id="O6" value="-0.864" spread="1.6578"/>
                    <measurement group_id="O7" value="-0.381" spread="1.0262"/>
                    <measurement group_id="O8" value="-1.167" spread="0.6389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.567" spread="1.0958"/>
                    <measurement group_id="O2" value="-0.559" spread="1.2972"/>
                    <measurement group_id="O3" value="-0.704" spread="1.1604"/>
                    <measurement group_id="O4" value="-1.095" spread="0.8393"/>
                    <measurement group_id="O5" value="-0.657" spread="1.1280"/>
                    <measurement group_id="O6" value="-0.680" spread="1.3724"/>
                    <measurement group_id="O7" value="-0.710" spread="1.2076"/>
                    <measurement group_id="O8" value="-1.196" spread="0.8728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.032" spread="1.3230"/>
                    <measurement group_id="O2" value="-0.807" spread="0.7085"/>
                    <measurement group_id="O3" value="-0.662" spread="1.1490"/>
                    <measurement group_id="O4" value="-1.448" spread="1.0766"/>
                    <measurement group_id="O5" value="-1.020" spread="1.4086"/>
                    <measurement group_id="O6" value="-0.923" spread="0.7435"/>
                    <measurement group_id="O7" value="-0.652" spread="1.1953"/>
                    <measurement group_id="O8" value="-1.501" spread="1.1190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.086" spread="1.2175"/>
                    <measurement group_id="O2" value="-0.913" spread="0.9640"/>
                    <measurement group_id="O3" value="-0.569" spread="1.2364"/>
                    <measurement group_id="O4" value="-1.501" spread="1.1683"/>
                    <measurement group_id="O5" value="-1.152" spread="1.3004"/>
                    <measurement group_id="O6" value="-1.054" spread="1.0421"/>
                    <measurement group_id="O7" value="-0.595" spread="1.2832"/>
                    <measurement group_id="O8" value="-1.329" spread="1.0122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.226" spread="1.2308"/>
                    <measurement group_id="O2" value="-0.744" spread="1.3057"/>
                    <measurement group_id="O3" value="-0.664" spread="1.3388"/>
                    <measurement group_id="O4" value="-1.312" spread="1.2535"/>
                    <measurement group_id="O5" value="-1.313" spread="1.3047"/>
                    <measurement group_id="O6" value="-0.821" spread="1.4747"/>
                    <measurement group_id="O7" value="-0.696" spread="1.3878"/>
                    <measurement group_id="O8" value="-1.275" spread="1.3575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-1.080" spread="1.4327"/>
                    <measurement group_id="O6" value="-1.159" spread="1.5168"/>
                    <measurement group_id="O7" value="-0.753" spread="1.3526"/>
                    <measurement group_id="O8" value="-1.265" spread="1.5105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.864" spread="1.4813"/>
                    <measurement group_id="O6" value="-0.846" spread="1.4961"/>
                    <measurement group_id="O7" value="-1.012" spread="1.7898"/>
                    <measurement group_id="O8" value="-1.224" spread="1.4763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-1.045" spread="1.4527"/>
                    <measurement group_id="O6" value="-1.209" spread="1.4589"/>
                    <measurement group_id="O7" value="-0.801" spread="1.5149"/>
                    <measurement group_id="O8" value="-1.120" spread="1.5781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.883" spread="1.4812"/>
                    <measurement group_id="O6" value="-1.093" spread="1.3147"/>
                    <measurement group_id="O7" value="-0.965" spread="1.5133"/>
                    <measurement group_id="O8" value="-0.886" spread="1.4063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.939" spread="1.6417"/>
                    <measurement group_id="O6" value="-1.198" spread="1.5077"/>
                    <measurement group_id="O7" value="-0.934" spread="1.5769"/>
                    <measurement group_id="O8" value="-0.761" spread="1.5076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.878" spread="1.4321"/>
                    <measurement group_id="O6" value="-1.267" spread="1.7114"/>
                    <measurement group_id="O7" value="-0.866" spread="1.5055"/>
                    <measurement group_id="O8" value="-0.653" spread="1.2861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.688" spread="1.2532"/>
                    <measurement group_id="O6" value="-1.248" spread="1.8622"/>
                    <measurement group_id="O7" value="-1.023" spread="1.6672"/>
                    <measurement group_id="O8" value="-1.057" spread="1.3742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.817" spread="1.3728"/>
                    <measurement group_id="O6" value="-1.232" spread="1.8140"/>
                    <measurement group_id="O7" value="-0.877" spread="1.6018"/>
                    <measurement group_id="O8" value="-0.914" spread="1.3941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.787" spread="1.3827"/>
                    <measurement group_id="O6" value="-0.794" spread="1.1386"/>
                    <measurement group_id="O7" value="-1.070" spread="1.7630"/>
                    <measurement group_id="O8" value="-0.948" spread="1.4326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.713" spread="1.3495"/>
                    <measurement group_id="O6" value="-0.688" spread="1.1425"/>
                    <measurement group_id="O7" value="-1.184" spread="1.8181"/>
                    <measurement group_id="O8" value="-0.890" spread="1.4800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.779" spread="1.2602"/>
                    <measurement group_id="O6" value="-0.850" spread="1.2527"/>
                    <measurement group_id="O7" value="-0.871" spread="1.8144"/>
                    <measurement group_id="O8" value="-0.818" spread="1.4112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-0.836" spread="1.2718"/>
                    <measurement group_id="O6" value="-1.152" spread="1.5226"/>
                    <measurement group_id="O7" value="-1.156" spread="1.9211"/>
                    <measurement group_id="O8" value="-0.682" spread="1.3581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Simple Disease Activity Index (SDAI) Values at Each Visit Based on LOCF</title>
        <description>The SDAI was calculated from tender joint counts of 28 (score range as 0-28), swollen joint counts of 28 (score range as 0-28), participant's global assessment of disease activity (score range as 0-10), physician global assessment of disease activity score (score range as 0-10), and CRP value (score range as 0-10). Total score ranged between 0-86. SDAI score of 26 or above=high disease activity, a value &gt;11 and &lt;=26=moderate disease activity and value &lt;=11=low disease activity, value &lt;=3.3=disease remission. Higher scores indicated higher disease activity. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Simple Disease Activity Index (SDAI) Values at Each Visit Based on LOCF</title>
          <description>The SDAI was calculated from tender joint counts of 28 (score range as 0-28), swollen joint counts of 28 (score range as 0-28), participant's global assessment of disease activity (score range as 0-10), physician global assessment of disease activity score (score range as 0-10), and CRP value (score range as 0-10). Total score ranged between 0-86. SDAI score of 26 or above=high disease activity, a value &gt;11 and &lt;=26=moderate disease activity and value &lt;=11=low disease activity, value &lt;=3.3=disease remission. Higher scores indicated higher disease activity. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.767" spread="13.8824"/>
                    <measurement group_id="O2" value="34.986" spread="16.9418"/>
                    <measurement group_id="O3" value="33.750" spread="11.5847"/>
                    <measurement group_id="O4" value="34.508" spread="14.2748"/>
                    <measurement group_id="O5" value="28.431" spread="11.1731"/>
                    <measurement group_id="O6" value="33.745" spread="17.7674"/>
                    <measurement group_id="O7" value="33.069" spread="11.7626"/>
                    <measurement group_id="O8" value="29.060" spread="6.6750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.620" spread="7.5960"/>
                    <measurement group_id="O2" value="-5.607" spread="7.1229"/>
                    <measurement group_id="O3" value="-6.100" spread="9.3523"/>
                    <measurement group_id="O4" value="-9.075" spread="8.0323"/>
                    <measurement group_id="O5" value="-6.054" spread="8.1006"/>
                    <measurement group_id="O6" value="-5.873" spread="8.0467"/>
                    <measurement group_id="O7" value="-6.362" spread="9.6807"/>
                    <measurement group_id="O8" value="-6.640" spread="6.2285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.767" spread="9.6279"/>
                    <measurement group_id="O2" value="-10.221" spread="11.8874"/>
                    <measurement group_id="O3" value="-6.836" spread="12.3932"/>
                    <measurement group_id="O4" value="-9.667" spread="5.8116"/>
                    <measurement group_id="O5" value="-8.062" spread="10.2120"/>
                    <measurement group_id="O6" value="-9.382" spread="11.9577"/>
                    <measurement group_id="O7" value="-6.392" spread="12.7832"/>
                    <measurement group_id="O8" value="-9.790" spread="6.4160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.260" spread="8.9168"/>
                    <measurement group_id="O2" value="-11.136" spread="18.0780"/>
                    <measurement group_id="O3" value="-5.586" spread="13.8352"/>
                    <measurement group_id="O4" value="-13.008" spread="5.7949"/>
                    <measurement group_id="O5" value="-10.023" spread="9.5951"/>
                    <measurement group_id="O6" value="-11.545" spread="20.3240"/>
                    <measurement group_id="O7" value="-4.985" spread="14.2086"/>
                    <measurement group_id="O8" value="-12.930" spread="6.3990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.793" spread="10.2078"/>
                    <measurement group_id="O2" value="-8.421" spread="17.5072"/>
                    <measurement group_id="O3" value="-7.643" spread="14.2285"/>
                    <measurement group_id="O4" value="-12.792" spread="8.4873"/>
                    <measurement group_id="O5" value="-9.023" spread="12.2819"/>
                    <measurement group_id="O6" value="-9.827" spread="18.8785"/>
                    <measurement group_id="O7" value="-7.815" spread="14.7942"/>
                    <measurement group_id="O8" value="-13.080" spread="9.0454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.760" spread="13.4649"/>
                    <measurement group_id="O2" value="-12.700" spread="11.1552"/>
                    <measurement group_id="O3" value="-8.521" spread="14.8650"/>
                    <measurement group_id="O4" value="-14.917" spread="10.6017"/>
                    <measurement group_id="O5" value="-11.762" spread="14.5004"/>
                    <measurement group_id="O6" value="-13.809" spread="12.3841"/>
                    <measurement group_id="O7" value="-8.446" spread="15.4692"/>
                    <measurement group_id="O8" value="-14.290" spread="10.4209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.167" spread="14.0241"/>
                    <measurement group_id="O2" value="-13.536" spread="13.7755"/>
                    <measurement group_id="O3" value="-6.907" spread="15.9803"/>
                    <measurement group_id="O4" value="-17.033" spread="11.3561"/>
                    <measurement group_id="O5" value="-12.708" spread="15.0684"/>
                    <measurement group_id="O6" value="-14.964" spread="15.3173"/>
                    <measurement group_id="O7" value="-7.285" spread="16.5677"/>
                    <measurement group_id="O8" value="-14.760" spread="8.8873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.107" spread="13.4448"/>
                    <measurement group_id="O2" value="-12.086" spread="16.8719"/>
                    <measurement group_id="O3" value="-7.171" spread="16.5184"/>
                    <measurement group_id="O4" value="-13.517" spread="12.9978"/>
                    <measurement group_id="O5" value="-14.946" spread="14.3229"/>
                    <measurement group_id="O6" value="-13.109" spread="19.0562"/>
                    <measurement group_id="O7" value="-7.569" spread="17.1230"/>
                    <measurement group_id="O8" value="-11.670" spread="12.9570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-13.708" spread="15.3680"/>
                    <measurement group_id="O6" value="-13.945" spread="20.3219"/>
                    <measurement group_id="O7" value="-7.954" spread="17.7855"/>
                    <measurement group_id="O8" value="-11.230" spread="13.3073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-12.169" spread="15.7365"/>
                    <measurement group_id="O6" value="-11.855" spread="18.5106"/>
                    <measurement group_id="O7" value="-8.708" spread="19.9022"/>
                    <measurement group_id="O8" value="-10.890" spread="14.0719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-12.569" spread="15.7788"/>
                    <measurement group_id="O6" value="-14.655" spread="19.3982"/>
                    <measurement group_id="O7" value="-8.600" spread="19.1369"/>
                    <measurement group_id="O8" value="-9.300" spread="17.4237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-11.438" spread="15.7793"/>
                    <measurement group_id="O6" value="-13.945" spread="18.4699"/>
                    <measurement group_id="O7" value="-10.215" spread="17.5279"/>
                    <measurement group_id="O8" value="-7.950" spread="17.2220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-11.277" spread="17.4198"/>
                    <measurement group_id="O6" value="-14.509" spread="19.4841"/>
                    <measurement group_id="O7" value="-9.285" spread="19.7611"/>
                    <measurement group_id="O8" value="-6.820" spread="16.7918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-11.685" spread="15.4954"/>
                    <measurement group_id="O6" value="-15.073" spread="20.5706"/>
                    <measurement group_id="O7" value="-9.731" spread="19.3009"/>
                    <measurement group_id="O8" value="-5.180" spread="14.7420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-8.469" spread="13.4793"/>
                    <measurement group_id="O6" value="-14.682" spread="22.2529"/>
                    <measurement group_id="O7" value="-10.369" spread="20.2755"/>
                    <measurement group_id="O8" value="-8.480" spread="15.8229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-9.577" spread="14.5219"/>
                    <measurement group_id="O6" value="-14.700" spread="21.6976"/>
                    <measurement group_id="O7" value="-9.177" spread="19.7402"/>
                    <measurement group_id="O8" value="-7.060" spread="15.2876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-9.269" spread="14.6406"/>
                    <measurement group_id="O6" value="-11.373" spread="16.1736"/>
                    <measurement group_id="O7" value="-10.915" spread="20.8181"/>
                    <measurement group_id="O8" value="-7.780" spread="16.2905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-8.677" spread="14.0686"/>
                    <measurement group_id="O6" value="-9.055" spread="15.1680"/>
                    <measurement group_id="O7" value="-10.831" spread="20.7975"/>
                    <measurement group_id="O8" value="-6.600" spread="16.3039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-9.077" spread="13.8200"/>
                    <measurement group_id="O6" value="-10.527" spread="18.0938"/>
                    <measurement group_id="O7" value="-9.054" spread="20.5279"/>
                    <measurement group_id="O8" value="-6.240" spread="15.4074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-9.122" spread="13.6836"/>
                    <measurement group_id="O6" value="-12.956" spread="19.9469"/>
                    <measurement group_id="O7" value="-10.985" spread="21.6004"/>
                    <measurement group_id="O8" value="-5.359" spread="15.1614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Disease Activity Index (CDAI) Values at Each Visit Based on LOCF</title>
        <description>The CDAI was calculated from tender joint counts of 28 (score range as 0-28), swollen joint counts of 28 (score range as 0-28), participant's global assessment of disease activity (score range as 0-10) and physician global assessment of disease activity (score range as 0-10). Total score ranged between 0-76. CDAI score of 22 or above=high disease activity, a value &gt;10 and &lt;=22=moderate disease activity, a value &lt;=10=low disease activity, and a value &lt;=2.8=disease remission. Higher scores indicated higher disease activity. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Disease Activity Index (CDAI) Values at Each Visit Based on LOCF</title>
          <description>The CDAI was calculated from tender joint counts of 28 (score range as 0-28), swollen joint counts of 28 (score range as 0-28), participant's global assessment of disease activity (score range as 0-10) and physician global assessment of disease activity (score range as 0-10). Total score ranged between 0-76. CDAI score of 22 or above=high disease activity, a value &gt;10 and &lt;=22=moderate disease activity, a value &lt;=10=low disease activity, and a value &lt;=2.8=disease remission. Higher scores indicated higher disease activity. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Baseline to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. LOCF imputation was applied for missing data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.687" spread="13.2790"/>
                    <measurement group_id="O2" value="32.486" spread="15.4890"/>
                    <measurement group_id="O3" value="30.657" spread="9.4928"/>
                    <measurement group_id="O4" value="32.833" spread="12.8294"/>
                    <measurement group_id="O5" value="27.492" spread="11.0621"/>
                    <measurement group_id="O6" value="31.918" spread="17.1251"/>
                    <measurement group_id="O7" value="29.969" spread="9.5103"/>
                    <measurement group_id="O8" value="28.250" spread="6.6991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.087" spread="7.2870"/>
                    <measurement group_id="O2" value="-5.629" spread="6.6070"/>
                    <measurement group_id="O3" value="-5.714" spread="9.0823"/>
                    <measurement group_id="O4" value="-8.942" spread="8.1025"/>
                    <measurement group_id="O5" value="-6.515" spread="7.7685"/>
                    <measurement group_id="O6" value="-6.100" spread="7.3778"/>
                    <measurement group_id="O7" value="-5.908" spread="9.4231"/>
                    <measurement group_id="O8" value="-6.530" spread="6.2243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.947" spread="9.5817"/>
                    <measurement group_id="O2" value="-9.593" spread="11.0959"/>
                    <measurement group_id="O3" value="-6.586" spread="12.2036"/>
                    <measurement group_id="O4" value="-10.400" spread="6.4684"/>
                    <measurement group_id="O5" value="-8.292" spread="10.1373"/>
                    <measurement group_id="O6" value="-9.373" spread="11.9883"/>
                    <measurement group_id="O7" value="-6.092" spread="12.5557"/>
                    <measurement group_id="O8" value="-9.770" spread="6.4534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.200" spread="9.0094"/>
                    <measurement group_id="O2" value="-10.807" spread="18.0182"/>
                    <measurement group_id="O3" value="-5.493" spread="13.6155"/>
                    <measurement group_id="O4" value="-13.433" spread="5.8262"/>
                    <measurement group_id="O5" value="-10.077" spread="9.6871"/>
                    <measurement group_id="O6" value="-11.845" spread="20.2785"/>
                    <measurement group_id="O7" value="-4.785" spread="13.9004"/>
                    <measurement group_id="O8" value="-13.000" spread="6.1248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.653" spread="11.3262"/>
                    <measurement group_id="O2" value="-7.986" spread="17.5102"/>
                    <measurement group_id="O3" value="-7.714" spread="12.9650"/>
                    <measurement group_id="O4" value="-13.192" spread="8.6300"/>
                    <measurement group_id="O5" value="-9.438" spread="11.8829"/>
                    <measurement group_id="O6" value="-9.645" spread="19.0353"/>
                    <measurement group_id="O7" value="-7.831" spread="13.4867"/>
                    <measurement group_id="O8" value="-13.410" spread="8.7252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.807" spread="12.8912"/>
                    <measurement group_id="O2" value="-12.279" spread="11.3618"/>
                    <measurement group_id="O3" value="-8.600" spread="13.6702"/>
                    <measurement group_id="O4" value="-15.550" spread="11.7076"/>
                    <measurement group_id="O5" value="-11.985" spread="13.8258"/>
                    <measurement group_id="O6" value="-13.709" spread="12.4778"/>
                    <measurement group_id="O7" value="-8.354" spread="14.1961"/>
                    <measurement group_id="O8" value="-14.570" spread="10.3295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.360" spread="13.3098"/>
                    <measurement group_id="O2" value="-13.129" spread="14.0345"/>
                    <measurement group_id="O3" value="-7.400" spread="14.5217"/>
                    <measurement group_id="O4" value="-17.592" spread="12.6565"/>
                    <measurement group_id="O5" value="-13.069" spread="14.2281"/>
                    <measurement group_id="O6" value="-14.864" spread="15.4843"/>
                    <measurement group_id="O7" value="-7.638" spread="15.0861"/>
                    <measurement group_id="O8" value="-15.130" spread="8.6208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.320" spread="12.8371"/>
                    <measurement group_id="O2" value="-11.779" spread="16.9787"/>
                    <measurement group_id="O3" value="-6.679" spread="14.8931"/>
                    <measurement group_id="O4" value="-13.983" spread="12.3963"/>
                    <measurement group_id="O5" value="-15.331" spread="13.5575"/>
                    <measurement group_id="O6" value="-13.255" spread="19.0433"/>
                    <measurement group_id="O7" value="-6.862" spread="15.4849"/>
                    <measurement group_id="O8" value="-12.320" spread="11.8315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-14.123" spread="14.6710"/>
                    <measurement group_id="O6" value="-13.964" spread="20.1448"/>
                    <measurement group_id="O7" value="-7.300" spread="15.9008"/>
                    <measurement group_id="O8" value="-11.980" spread="12.1211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-12.646" spread="14.8310"/>
                    <measurement group_id="O6" value="-11.945" spread="18.0326"/>
                    <measurement group_id="O7" value="-7.585" spread="17.9281"/>
                    <measurement group_id="O8" value="-11.580" spread="12.9276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-13.377" spread="14.4734"/>
                    <measurement group_id="O6" value="-14.755" spread="19.2637"/>
                    <measurement group_id="O7" value="-7.438" spread="17.2899"/>
                    <measurement group_id="O8" value="-9.970" spread="16.6191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-12.192" spread="14.5243"/>
                    <measurement group_id="O6" value="-14.200" spread="18.3184"/>
                    <measurement group_id="O7" value="-9.792" spread="17.3534"/>
                    <measurement group_id="O8" value="-8.960" spread="16.2228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-12.354" spread="16.1397"/>
                    <measurement group_id="O6" value="-14.891" spread="19.2430"/>
                    <measurement group_id="O7" value="-8.785" spread="18.0594"/>
                    <measurement group_id="O8" value="-7.680" spread="16.0389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-12.677" spread="14.3445"/>
                    <measurement group_id="O6" value="-15.282" spread="20.3093"/>
                    <measurement group_id="O7" value="-8.692" spread="17.4611"/>
                    <measurement group_id="O8" value="-6.160" spread="14.0400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-9.300" spread="12.3597"/>
                    <measurement group_id="O6" value="-14.936" spread="21.9162"/>
                    <measurement group_id="O7" value="-9.208" spread="18.0779"/>
                    <measurement group_id="O8" value="-9.200" spread="15.1983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-10.823" spread="13.4309"/>
                    <measurement group_id="O6" value="-15.327" spread="21.3345"/>
                    <measurement group_id="O7" value="-8.138" spread="17.6150"/>
                    <measurement group_id="O8" value="-7.730" spread="14.7041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-10.415" spread="13.4300"/>
                    <measurement group_id="O6" value="-11.955" spread="15.8809"/>
                    <measurement group_id="O7" value="-9.877" spread="18.6515"/>
                    <measurement group_id="O8" value="-8.470" spread="15.7053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-9.785" spread="12.9341"/>
                    <measurement group_id="O6" value="-9.527" spread="14.8393"/>
                    <measurement group_id="O7" value="-9.962" spread="19.4745"/>
                    <measurement group_id="O8" value="-7.370" spread="15.5947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-10.523" spread="12.9377"/>
                    <measurement group_id="O6" value="-10.927" spread="17.8324"/>
                    <measurement group_id="O7" value="-7.954" spread="18.5732"/>
                    <measurement group_id="O8" value="-6.910" spread="14.6880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-10.300" spread="12.7026"/>
                    <measurement group_id="O6" value="-13.245" spread="19.5791"/>
                    <measurement group_id="O7" value="-10.046" spread="19.5472"/>
                    <measurement group_id="O8" value="-6.330" spread="14.3787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a European League Against Rheumatism (EULAR) Good, Moderate or No Response Using DAS28-ESR at Each Visit Based on NRI</title>
        <description>The Disease Activity Score Based on 28-joints Count-ESR based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 &lt;=3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to &lt;=5.1 or change from baseline &gt;0.6 to &lt;=1.2 with DAS28 &lt;=5.1; non-responders: change from baseline &lt;=0.6 or change from baseline &gt;0.6 and &lt;=1.2 with DAS28 &gt;5.1. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a European League Against Rheumatism (EULAR) Good, Moderate or No Response Using DAS28-ESR at Each Visit Based on NRI</title>
          <description>The Disease Activity Score Based on 28-joints Count-ESR based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 &lt;=3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to &lt;=5.1 or change from baseline &gt;0.6 to &lt;=1.2 with DAS28 &lt;=5.1; non-responders: change from baseline &lt;=0.6 or change from baseline &gt;0.6 and &lt;=1.2 with DAS28 &gt;5.1. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EULAR Response at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Response at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a EULAR Good, Moderate or No Response Using DAS28-CRP at Each Visit Based on NRI</title>
        <description>The Disease Activity Score Based on 28-joints Count-CRP based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 &lt;=3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to &lt;=5.1 or change from baseline &gt;0.6 to &lt;=1.2 with DAS28 &lt;=5.1; non-responders: change from baseline &lt;=0.6 or change from baseline &gt;0.6 and &lt;=1.2 with DAS28 &gt;5.1. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a EULAR Good, Moderate or No Response Using DAS28-CRP at Each Visit Based on NRI</title>
          <description>The Disease Activity Score Based on 28-joints Count-CRP based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 &lt;=3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to &lt;=5.1 or change from baseline &gt;0.6 to &lt;=1.2 with DAS28 &lt;=5.1; non-responders: change from baseline &lt;=0.6 or change from baseline &gt;0.6 and &lt;=1.2 with DAS28 &gt;5.1. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EULAR response at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR response at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Good response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved SDAI Remission at Each Visit Based on NRI</title>
        <description>The SDAI was calculated from tender joint counts of 28 (score range as 0-28), swollen joint counts of 28 (score range as 0-28), participant's global assessment of disease activity (score range as 0-10), physician global assessment of disease activity score (score range as 0-10), and CRP value (score range as 0-10). Total score ranged between 0-86. SDAI score of 86 or above=high disease activity, a value &gt;11 and &lt;=26=moderate disease activity, a value &gt;=3.4 and &lt;=11=low disease activity. Higher scores indicated higher disease activity. SDAI Remission was defined as SDAI score &lt;=3.3. Data for Core Treatment Phase from Week 0-10 is reported according to participant's re-randomization in four arms at Week 12. Data reported for Extension Phase from Week 2 to Week 24, is same data for Core Treatment Phase, but excluding participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved SDAI Remission at Each Visit Based on NRI</title>
          <description>The SDAI was calculated from tender joint counts of 28 (score range as 0-28), swollen joint counts of 28 (score range as 0-28), participant's global assessment of disease activity (score range as 0-10), physician global assessment of disease activity score (score range as 0-10), and CRP value (score range as 0-10). Total score ranged between 0-86. SDAI score of 86 or above=high disease activity, a value &gt;11 and &lt;=26=moderate disease activity, a value &gt;=3.4 and &lt;=11=low disease activity. Higher scores indicated higher disease activity. SDAI Remission was defined as SDAI score &lt;=3.3. Data for Core Treatment Phase from Week 0-10 is reported according to participant's re-randomization in four arms at Week 12. Data reported for Extension Phase from Week 2 to Week 24, is same data for Core Treatment Phase, but excluding participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Remission at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O2" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O2" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="8.3" lower_limit="0.00" upper_limit="23.97"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O2" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="8.3" lower_limit="0.00" upper_limit="23.97"/>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="8.3" lower_limit="0.00" upper_limit="23.97"/>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="20.0" lower_limit="0.00" upper_limit="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="27.3" lower_limit="0.95" upper_limit="53.59"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="27.3" lower_limit="0.95" upper_limit="53.59"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved CDAI Remission at Each Visit Based on NRI</title>
        <description>The CDAI was calculated from tender joint counts of 28 (score range as 0-28), swollen joint counts of 28 (score range as 0-28), participant's global assessment of disease activity (score range as 0-10), and physician global assessment of disease activity score (score range as 0-10). Total score ranged between 0-76. CDAI score of 76 or above=high disease activity, a value &gt;10 and &lt;=22=moderate disease activity, a value &gt;2.9 and &lt;=10=low disease activity. Higher scores indicated higher disease activity. CDAI Remission was defined as CDAI score &lt;=2.8. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved CDAI Remission at Each Visit Based on NRI</title>
          <description>The CDAI was calculated from tender joint counts of 28 (score range as 0-28), swollen joint counts of 28 (score range as 0-28), participant's global assessment of disease activity (score range as 0-10), and physician global assessment of disease activity score (score range as 0-10). Total score ranged between 0-76. CDAI score of 76 or above=high disease activity, a value &gt;10 and &lt;=22=moderate disease activity, a value &gt;2.9 and &lt;=10=low disease activity. Higher scores indicated higher disease activity. CDAI Remission was defined as CDAI score &lt;=2.8. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Remission at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O2" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O2" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O2" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="8.3" lower_limit="0.00" upper_limit="23.97"/>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="8.3" lower_limit="0.00" upper_limit="23.97"/>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="20.0" lower_limit="0.00" upper_limit="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="27.3" lower_limit="0.95" upper_limit="53.59"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Boolean Remission at Each Visit Based on NRI</title>
        <description>Boolean remission criteria was defined as: tender joint count 68 &lt;=1; swollen joint count 66 &lt;=1; CRP &lt;=1 mg/dL; and disease activity assessments VAS (mm) by participants &lt;=10. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
        <time_frame>Core Treatment Phase: Weeks 2, 4, 8, 12, 16, 20 and 24; Extension Phase: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72</time_frame>
        <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O2">
            <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
            <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O3">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O4">
            <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
            <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
          </group>
          <group group_id="O5">
            <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O6">
            <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O7">
            <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
          <group group_id="O8">
            <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
            <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Boolean Remission at Each Visit Based on NRI</title>
          <description>Boolean remission criteria was defined as: tender joint count 68 &lt;=1; swollen joint count 66 &lt;=1; CRP &lt;=1 mg/dL; and disease activity assessments VAS (mm) by participants &lt;=10. Data for the Core Treatment Phase from Week 0-10 is reported according to the participant's re-randomization in four arms at Week 12. Data reported for the Extension Phase from Week 2 to Week 24, is the same data for the Core Treatment Phase, but excluding the participants who received at least 1 dose of study drug after Week 24 and had at least 1 postdose primary efficacy measurement after Week 24 to Week 72.</description>
          <population>FAS included all re-randomized participants who received at least 1 dose of study drug, and had at least 1 primary efficacy measurement. Here number analyzed &quot;n&quot; were the participants who were evaluable for the outcome measure for given time points. Non-responders (due to early discontinuation or other reasons were considered non-responders) imputation was applied for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Remission at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="0.00" upper_limit="30.54"/>
                    <measurement group_id="O2" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="8.3" lower_limit="0.00" upper_limit="23.97"/>
                    <measurement group_id="O5" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.00" upper_limit="20.63"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.00" upper_limit="22.18"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="18.2" lower_limit="0.00" upper_limit="40.97"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.00" upper_limit="26.08"/>
                    <measurement group_id="O7" value="15.4" lower_limit="0.00" upper_limit="35.00"/>
                    <measurement group_id="O8" value="10.0" lower_limit="0.00" upper_limit="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug up to 104 Weeks (Treatment Phase: From the first dose of study drug till Week 24; Extension Phase: Post Week 24 till Week 104)</time_frame>
      <desc>SAS included participants who received at least 1 dose of study drug and had at least 1 postdose safety assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Core Treatment Phase: Placebo</title>
          <description>During the Core Treatment Phase, participants received E6011-matched placebo, infusion, subcutaneously, at Weeks 0, 1, and 2 and then every 2 weeks up to Week 10.</description>
        </group>
        <group group_id="E2">
          <title>Core Treatment Phase: E6011 400 mg</title>
          <description>During the Core Treatment Phase, participants received E6011 400 mg, infusion, subcutaneously, at Weeks 0, 1, and 2 and then every 2 weeks up to Week 10.</description>
        </group>
        <group group_id="E3">
          <title>Core Treatment Phase: Placebo Then E6011 200 mg</title>
          <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
        </group>
        <group group_id="E4">
          <title>Core Treatment Phase: Placebo Then E6011 400 mg</title>
          <description>Participants who received Placebo and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
        </group>
        <group group_id="E5">
          <title>Core Treatment Phase: E6011 400 mg Then E6011 200 mg</title>
          <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 200 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
        </group>
        <group group_id="E6">
          <title>Core Treatment Phase: E6011 400 mg Then E6011 400 mg</title>
          <description>Participants who received E6011 400 mg and completed Week 10 evaluations were re-randomized at Week 12 in the Core Treatment Phase to receive E6011 400 mg, infusion, subcutaneously every 2 weeks between Weeks 12 and 22. Participants who completed evaluations at Week 24 of the Core Treatment Phase entered the Extension Phase.</description>
        </group>
        <group group_id="E7">
          <title>Extension Phase: Placebo Then E6011 200 mg Then E6011 200 mg</title>
          <description>Participants who received Placebo up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
        </group>
        <group group_id="E8">
          <title>Extension Phase: Placebo Then E6011 400 mg Then E6011 200 mg</title>
          <description>Participants who received Placebo up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
        </group>
        <group group_id="E9">
          <title>Extension Phase: E6011 400 mg Then E6011 200 mg Then E6011 200 mg</title>
          <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 200 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
        </group>
        <group group_id="E10">
          <title>Extension Phase: E6011 400 mg Then E6011 400 mg Then E6011 200 mg</title>
          <description>Participants who received E6011 400 mg up to Week 10 followed by E6011 400 mg from Weeks 12 to 22 during the Core Treatment Phase continued receiving E6011 200 mg, infusion, subcutaneously every 2 weeks up to Week 102 in the Extension Phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint destruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eustachian tube patulous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dental necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bacterial diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dermatophytosis of nail</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dislocation of vertebra</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cell marker increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypovitaminosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Joint destruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Intervertebral disc compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chloasma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Poor peripheral circulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Inquiry Service.</name_or_title>
      <organization>Eisai Co., Ltd.</organization>
      <email>eisai-chiken_hotline@hhc.eisai.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

